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Asthma, a chronic inflammatory disease of the lungs affecting approximately 300 million 
people worldwide involves airway inflammation that is associated with airway remodelling. 
The IL-4 receptor alpha (IL-4Rα), which is the signal transducing receptor chain for IL-4 and 
IL-13, is known to play an important role in airway hyperreactivity (AHR) and lung 
pathology in asthma. Mouse models of AAD mimicking features of asthma such as airway 
hyperreactivity (AHR) and inflammation have demonstrated an important role for the IL-
4Rα, IL-4 and IL-13 in the pathology of this disease. However, the effects of IL-4 and IL-13 
signaling through specific cell types in allergic asthma remain to be elucidated. The aim of 
our study is to investigate the role of IL-4/IL-13 target cells in allergic airway disease using 
comparative experimental cell type-specific IL-4Rα deficient mouse models of chronic 




littermate control mice, IL-4Rα
-/-
 mice and mice with cell specific impairment of 
IL-4Rα on CD4
+









) were sensitized subcutaneously with 25 micrograms of ovalbumin (OVA) adsorbed to 
alum at days 0, 7, 14 and 21 and subsequently challenged intranasally with 20 micrograms of 
OVA twice weekly for four weeks. Airway hyperreactivity (AHR) was measured by flexivent 
in response to increasing doses of methacholine and samples were taken for analysis. 
 
Airway resistance and elastance were significantly increased in OVA-challenged IL-4Rα
-/lox 






OVA mice had significantly decreased airway resistance and elastance, reduced airway 
inflammation, mucus hypersecretion and airway eosinophilia compared to OVA IL-4Rα
-/lox 






mice. Compared to IL-4Rα
-/lox 
littermate 
control mice sensitized and challenged with PBS, OVA-challenged IL-4Rα
-/lox 
littermate 
control mice had increased AHR after methacholine challenge. Allergic airway inflammation 





















Together, these results suggest that IL-4/IL-13-activated alternative macrophages are 
involved in AHR and IL-4-promoted Th2 cells are important in allergic inflammation and 





































1 General Introduction 
 
1.1 Overview of Allergy and Asthma 
 
1.1.1 Allergy 
Allergies are the most common chronic immunological disorders where an abnormal reaction 
of a person’s immune system occurs in response to harmless substances in the environment. 
Allergic diseases include anaphylaxis, angioedema, asthma, food allergies, eczema, rhinitis 
and urticaria. There is a dramatic increase in the prevalence of allergic diseases globally with 
about 30-40% population being affected by it. The greatest burden of the rising trend of these 
diseases in the last few decades is found among children.
1
 The two broad categories of risk 
factors for allergy include host and environmental factors.
2
 The role of host heredity and 
genetic factors in the disposition to allergic diseases has been reported. However genetic 
factors in the host alone cannot provide insights into the rec nt increased incidence of allergic 
diseases even though polymorphisms in several candidate genes of allergic diseases have 
been reported. 
3 
Individuals with a known family history of allergies are more prone to 
develop allergies in their lifetime.  
Allergy is a type I hypersensitivity reaction mediated by allergen specific immunological 
mechanisms causing excessive activation of mast cells and basophils by immunoglobulin E 
resulting in an inflammatory response which can range from uncomfortable to life 
threatening. Type I reactions, a class of humoral immune reactions occurs within minutes of 
contact with the allergen and due to its rapid onset are termed immediate hypersensitivity 
reactions. They are predominantly mast cell-mediated and are caused specifically by antibody 
of the IgE isotype which are capable of binding to Fc-receptors for IgE on mast cells found in 
tissue. Cross-linking of these membrane-bound IgE's by specific antigen results in mast cell 
degranulation releasing proallergic mediators such as histamine, leukotrienes and 
prostaglandins from mast cells and basophils. This eventually results in the myriad symptoms 
of allergy. 
4 
The interplay between gene-gene, gene–environment, gene–gene–environment and gene–
environment–environment interactions contributes to the risk of developing asthma thus 

















The hygiene hypothesis is supported by various epidemiological studies and 
explained the increased incidence of these diseases in developed countries thereby providing 
a vital framework in understanding the allergic diseases. 
6, 7 
Even though the reduction in the 
risk of developing allergies in children on exposure to certain infections in early childhood 





explanations for this hypothesis are either early exposure to the allergen induces the 
development of a protective Th1 type immune response to the allergen, preventing a Th2 type 
immune response leaving the body more susceptible to developing Th2 induced disease.
7, 11 






Any antigenic substance responsible for eliciting an allergic response by stimulating a type-I 
hypersensitivity reaction through IgE responses is termed an allergen. Table 1.1 below lists 
some of the common allergens and their sources. Allergens can only be effective in causing 
an allergic reaction in an individual if there is previous sensitization to the allergen 
characterised by the induction of the IgE response directed against the allergen in the tissues 
and includes modulation of dendritic cells, B cells and T cells.
13
 
Table 1.1: Common allergens 
Source of allergen  Examples 
Food Eggs, fish, fruit, milk, nuts 
House dust Dander from house pets, mites 
Mould Food mould, plant mould 
Plant Oils Oak, poison ivy, sumac 
Pollen from grasses, trees and weeds Timothy grass, elm, ragweed 


















Allergens are mostly proteins that are capable of reaching and stimulating immune cells 
capable of inducing an allergic response.
14 
An allergic reaction is usually caused by any form 
of exposure to the dietary or environmental allergens via one of the following routes— 
ingestion (natural or artificial food products), inhalation through the air (pollen), direct 
contact (with the skin) or injection (drugs or insect bites). 
Allergens are named using the systematic nomenclature of the Allergen Nomenclature Sub-
Committee of the World Health Organization and International Union of Immunological 
Societies. The system uses abbreviated Linnaean genus and species name of their source as 
follows: first three letters of the genus name, first letter of the species and an Arabic number 




1.1.3 Immunological mechanisms of allergy 
 
Both cellular and humoral immune responses are involved in allergies. Allergen specific IgE 
antibodies induce most allergic responses in humans. Any IgE-mediated reaction to common 
environmental allergens is called atopy and has got a strong genetic predisposition. In most 
humans, significant IgE responses are m unted against parasitic infections. In atopic 
individuals, non-parasitic antigens stimulate inappropriate IgE production, leading to type I 
hypersensitivity. Sensitivities vary widely from one person to another. A very broad range of 
substances can be allergens to sensitive individuals. IgG antibodies (e.g. drug induced 




Sequence of events in allergies 
Immune responses to allergies are divided in-to two main phases: 
 
1) Sensitization phase and  
2) Reaction Phase 
 
During the sensitization phase, an immune response to the allergen is established by the 
immune system on encounter with the allergen for the first time resulting in the induction of 















through its Fc portion. Dendritic cells (DCs) or antigen presenting cell (APCs) then present 
the allergen to the undifferentiated T-helper cells which then undergo differentiation and 
clonal expansion of allergen-specific T helper 2 (Th2) cells into allergen specific Th2 cells in 
the presence of IL-4 produced by various cells of the adaptive immune system.
19 
B cells are 
then stimulated by allergen specific Th2 cells to produce allergen specific IgE or IgG1 
antibodies. The establishment of an allergen specific T cell and B cell response to the allergen 
is critical for the further development of the allergic disease. These cells activate a memory 
response on second encounter with the allergen.  
 
During the reaction phase, re-exposure to the allergen results in the binding of the allergen to 
mast-cell-bound IgE antibody, causing IgE cross-linking. The crosslinking of mast-cell and 
basophil cell-surface with the high-affinity receptor for IgE (Fc RI) bound IgE by allergens 
causes the release of large, basophilic granules into the tissues by the process of 
degranulation releasing a variety of inflammatory mediators : chemokines (such as CXC-
chemokine ligand 8 (CXCL8), CC-chemokine ligand 4 (CCL4), cytokines (such as IL-4, IL-5 
and IL-13), lipid mediators (such as leukotrienes, prostaglandins), proteases, and vasoactive 
amines ( histamine)
20 
thereby increasing vascular permeability and smooth muscle cell 
contraction.
 21 
The expression of these cytokines recruits Th2 cells and eosinophils which 
play an essential role in the late phase of allergic reactions and subsequently chronic 
inflammation. Histamines, one of the chemoattractant for mast cells and eosinophils increases 
the vascular permeability enabling the influx of inflammatory cells at the site of the allergic 
reaction which in turn establish the chronic and late phase of AAD.
22 
Eosinophils and 
basophils in circulation and mast cells in tissue are the key players in allergic reactions. 
Allergens bind to IgE on the surface of mast cells through histamine receptors releasing 
histamines stored in their granules causing injury to the surrounding tissue including blood 
vessels and nerve cells. Interaction of histamine with receptors on blood vessels causes 
increased leakiness, leading to the fluid collection, swelling and increased redness. IgE 
receptor also stimulates pain receptors, making tissue more sensitive and irritable.  
 
1.1.4 Diagnosis and treatment of allergy 
Allergy testing involves skin or blood tests to determine which allergen elicit an immune 
response. Skin tests are normally done due to their rapidness, reliability and cost 















the skin to see if a reaction develops. The three types of skin tests are skin prick test, 
intradermal test and skin patch test. Blood tests utilize ELISA to look for allergen specific 
IgE antibodies in blood. Other laboratory testing methods include radioallergosorbent testing 
(RAST) or an immunoassay capture test (ImmunoCAP, UniCAP, or Pharmacia CAP).
23 
Common management for allergic conditions include avoidance of known allergens. 
However normally this is practically impossible. The treatments include use of variety of 
medications and also allergen-specific desensitization (immunotherapy).  Medications such as 
anti-histamines specifically prevent allergic symptoms, steroids suppress immune responses, 
and decongestants reduce the symptoms of allergy. These medications are mostly 
administered orally. However, epinephrine which is used to treat anaphylactic reactions is 
injected. Immunotherapy uses injected allergens to desensitize the body's response.
24 
1.1.5 Asthma 
Asthma is a severe chronic inflammatory disease of the lungs. According to the WHO 
estimates, worldwide approximately 300 million people are affected by asthma, with 180 000 
deaths resulting annually from severe asthma attacks.
25 
Asthma poses a serious public health 
problem in all countries across the globe as shown in figure 1. Over 80% of asthma deaths 
occur in low and lower-middle income countries. Asthma has become the most common 
chronic disease among children and is one of the major causes of hospitalization among those 
younger than 15 years of age.
26 
Triggers such as indoor allergens (house dust mites, pet hair 
or dander etc),outdoor allergens (pollens and mould), cold air, tobacco smoke, chemical 
irritants in the air or in the food, respiratory infections (common cold), extreme emotions, 
physical exercise, certain medication such as aspirin, non-steroid anti-inflammatory drugs, 
beta-blockers etc can cause asthma. 
Asthma is characterised by recurrent episodes of symptoms such as coughing, wheezing, 
chest tightness, and shortness of breath, which vary in severity and frequency from person to 
person. In severe cases it can be fatal.
27 
Even though the primary causes of asthma are not 
completely understood, genetic predisposition combined with environmental exposure to 
certain inhaled substances and particles were identified as the strongest risk factors for 
developing asthma.
28 
The symptoms of asthma are caused by airway obstruction due to 
bronchoconstriction, mucus hypersecretion and inflammation of the airways that leads to 
airway wall thickening.
29 



















T helper 2 (Th2) responses occur in most asthma and mouse models of asthma. Increased 
numbers of alternatively activated macrophages and natural killer T cells have also been 
found in asthmatic airways 
31, 32 
and asthma exacerbations are associated with neutrophils.
 33 
There is also evidence to suggest that asthmatics have intrinsic differences in the epithelial 
cells of their airways that lead to impaired barrier function and enhanced signalling with 
underlying immune and mesenchymal cells.
27, 34 
Differences in smooth muscle cells isolated 
from asthmatic patients including increased proliferation and increased production of 
connective tissue growth factor have been reported 
35
. A number of factors may therefore 
contribute to the airway obstruction that is associated with acute asthma attacks. 
Asthma cannot be cured. However, appropriate management of the disease using short-term 
and/or long-term medications can control and prevent the symptoms and exacerbations, thus 
enabling the patients a good quality of life. Avoidance of known triggers and exposure to risk 
factors is also important in controlling asthma. Current asthma therapy does not seem to be 
effective against certain types of asthma, particularly severe asthma as it uses chronic 
medication which has to be taken life long, involves certain side-effects and combat only the 
symptoms of the disease and not the disease itself. The most effective treatment for asthma is 
corticosteroid therapy which involves suppression of leukocytes, particularly Th2 cells.
36, 37 
However, limited efficacy has been shown with agents such as cyclosporine that suppress 
activated T cells.
38, 39 
Furthermore, the results of clinical trials that have tested monoclonal 




Asthma does not kill on the scale of chronic obstructive pulmonary disease (COPD) or other 
chronic diseases, but failure to use appropriate medications or to adhere to treatment can lead 
to death.
40 
Also in developing countries, lack of access to hospitals and other health care 

















Figure 1. Global prevalence of asthma. Map showing the variation in the prevalence of 



















Figure 2. Global fatality rates of asthma. Map showing the variation in the fatality rates of 






















1.2 Mouse models of Allergic Airway Disease (AAD) 
Mouse models of allergic airway disease have been extremely useful in understanding the 
pathology of asthma as they share lot of similarities with human asthma.
 43 
In order to induce 
allergic reactions in mice, sensitization with ovalbumin (OVA) with the adjuvant is carried 
out first followed by the nasal administration of OVA without the adjuvant. These models are 
widely used to investigate the underlying immunological mechanisms of OVA- induced 
allergic airway inflammation. 
44-50 












been used in other murine models of AAD.  
Allergic airway disease (AAD) is a complex inflammatory disease involving many cell types, 
mediators and tissue responses. It involves a typical Th2 type immune response.  Systemic 
immunization prior to airway exposure has been used in various murine models. Some of 
these models require systemic immunization of allergen prior to challenge and these allergens 
always need to be administrated together with an adjuvant (aluminium hydroxide (alum) or 
cholera toxin). The mice are systemically sensitised by repeated intra peritoneal (i.p) injection 
of allergen and adjuvant.  
Inhalation of allergens in mice induces responses that are similar to human asthma: 
Production of Th2 cytokines, goblet cell hyperplasia, bronchoalveolar lavage and pulmonary 
neutrophil response, followed by eosinophil response, mast cell degranulation and IgE 
production, airway hyper responsiveness (AHR) to cholinergic stimuli that includes rapid and 
delayed development of increased airway resistance as shown in figure 3. Both human 
asthma and mouse models show memory responses as well.
56 
However, studies in both 
animal and human have demonstrated the development of tolerance on repeated airway 
exposure to an antigen.
49, 57-62 
indicating that instead of tolerance it leads to the disease 
development in asthma. 
 
Chronic remodelling with smooth muscle hyperplasia and subepithelial fibrosis has been 
shown by some mouse models as shown in figure 3 (c).
63 
Both human asthma and some 
mouse models are suppressed to some extent by leukotriene antagonists and leukotriene 
receptor antagonists, mast cell depletion, IgE antagonists, phosphodiesterase 4 antagonists, 
and corticosteroids.
64 















influences susceptibility to AAD in both mice and human subjects.
65
 In humans, allergies 
develop only on exposure to the allergen and not after sensitization.
66-68 
 
Thus, murine models have contributed to our understanding of the mechanism of 
development and pathology of AAD. The use of knockout mice has certainly added value to 
our understanding of the roles of specific molecules and cytokines in these models. However, 
different strains of mice respond differently in these models displaying contrasting 
phenotypes in different backgrounds.
69 
Comparative animal models of AAD using C57BL/6 
and BALB/c backgrounds have also been reported. 
70 
Mouse models that replicate some of 
the features of asthma have been used extensively to try to uncover the underlying 
mechanisms of disease. 
71-74 
T helper 2 (Th2) responses are associated with mouse models of asthma and human asthma 
by production of cytokines contributing to the infiltration of eosinophils (IL-5, eotaxin), 
mucus hypersecretion (IL-13) and IgE production (IL-4), with IL-13 being associated with 
both allergic and non-allergic asthma. 
75-81
 These mouse models have demonstrated that the 
IL- -4 and IL-13 are important in the induction of Th2-driven airway 
inflammation, mucus hypersecretion and airway hyperreactivity.
74, 82-84 
In effect this demonstrates that the mechanisms behind asthma pathogenesis are not fully 
understood. Individual cytokines have a wide range of effects which may be beneficial or 
deleterious depending upon the cells through which they signal. By determining the cell 
specific effects of cytokine signalling, we will be able to uncover the pathways that are 
important for the elicitation of airway disease and identify downstream effector molecules 




















Figure 3.  Immunological mechanism of asthma. Progression of asthma can involve three 
phases. In acute phase (a) allergen-induced activation of mast cells releases pro-inflammatory 
cytokines and mediators, leading to acute bronchoconstriction and airway obstruction, which 
leads to the chronic phase (b) characterized by activation of Th2 cells and macrophages, 
recruitment and degranulation of eosinophils leading to changes in the airway causing airflow 
obstruction and increase in airway responsiveness. This can progress further to remodelling 
changes (c) leading to permanent irreversible alterations in the airway architecture. Figure 




























1.3 Immunological mechanisms of AAD 
AAD, an inflammatory disease is caused by a Th2 type immune response. The immediate 
reactions of AAD are mediated by the release of inflammatory mediators by IgE. However, 
the mechanisms of late and chronic phases of AAD are poorly understood. A complex 
interaction of immune cells, cytokines and resident cells cause the development of disease 
symptoms of AAD where Th2 cytokines play a central role in this processes. IL-4 is critical 
for the development of Th2 cells from uncommitted Th0 cells and is also important for 
isotype switching of B cells from IgG to IgE. Mice deficient in IL-4 showed abrogated Th2 
response.
86
 IL-4 neutralization during the sensitisation phase caused a reduction in airway 
hyperresponsiveness, eosinophilia and allergen-specific IgE production.
19
 However, IL-4 
neutralisation during the effector phase did not have an effect on AAD. 
45 
 
IL-13 produced by Th2 cells, mast cells, basophils and eosinophils promotes development of 
alternatively activated macrophages that have been hypothesized to play a role in allergies.
875  
Studies have shown that main symptoms of allergic asthma were induced by IL-13 
independently of IL-4 and IL-13 is mainly responsible for goblet cell hyperplasia and mucus 
production
. 19, 75   
The induction of AHR by IL-13 through a direct effect on contraction of 
smooth muscle cells of the airways has also been reported.
88 
Murine studies have also 
confirmed a common signalling pathway ie IL-4Rα for both IL-4 and IL-13.89 
 
Besides IL-4 and IL-13, there are other cytokines that contribute to the development of AAD. 
IL-5 plays a significant role in AAD through inducing eosinophils at inflammation sites, 
since it is critically involved in the growth, differentiation, maturation, recruitment and 
activation of eosinophils.
90-93  
The role of IL-5 in the pathogenesis of asthma has been 
supported by various lines of experimental evidence. IL-5 deficient mice showed impaired 
numbers of eosinophils in the periphery and the lung after allergen challenge. 
45, 94-97 
In 
Clinical trials of asthmatic patients, a humanized blocking antibody specific for IL-5 
(mepolizumab) although showed significant reduction in eosinophils had no effect on 
improving the disease. 
98-101 
 
In mice, IL-9 blockade inhibited pulmonary eosinophilia, mucus hypersecretion, and AHR 



















The functional role of IL-17 in asthma is unclear, since studies have shown a dual role for IL-
17. IL-17 seems to be involved in allergic sensitization of animal models by inhibiting 
eosinophilic inflammation in sensitized animals and is known to induce proinflammatory 
cytokines contributing to acute inflammation. 
103 
Murine models have shown that IL-25 (IL-
17E) produced by Th2 cells, mast cells, and epithelial cells induces the expression of IL-4, 
IL-5, and IL-13, resulting in inflammation mediated by eosinophils, increased IgE 
production, and AHR in mice. 
104 
Expression of IL-17 in the effector phase of allergic asthma 
reduces allergic symptoms by inhibiting dendritic cell functions and expression of IL-4 and 
IL-5.
105 
TH17 cells are characterized by IL-17 (or IL-17A), IL-17F, IL-6, TNF-α, and IL-22 
expression. IL-17A and IL-17F release neutrophil chemoattractants CXCL1 and CXCL8 
from airway epithelial cells and airway smooth muscle cells and are responsible for 
neutrophil-mediated inflammation.
106
 Thus IL-17 plays an essential a role in the neutrophilic 
inflammation of severe asthma. Increased expression of mucin-encoding genes (MUC5AC 
and MUC5B) in human airway epithelial cells by IL-17 has also been reported.
107
 Human 
studies have also shown the increased levels of IL-17A in the sputum of individuals with 
asthma and an increase in Th17 cells in the airways.
108, 109 
Human studies have also 
confirmed that the secretion of Th2 cytokines is enhanced by IL-25.
110, 111 
Blocking of IL-25 
in mice inhibited the development of AHR in response to allergens.
112 
1.4 IL-4 Receptor alpha (IL-4Rα): common receptor for IL-4 and IL-13 
 
The fundamental Th2-associated cytokines, IL-4 and IL-13, play a key role in allergic 
sensitisation and in the development of symptoms for allergy as established by a range of 
experimental models and epidemiological studies.
113
 The genes for both these cytokines are 
closely linked on both human and mouse chromosomes.
114 
 
1.4.1 IL-4 and IL-13 Receptors 
IL-4 and IL-13 have similar tertiary structures even though their amino acid homology amino 
is low.
115  
IL-4 and IL-13 show overlapping functions, which is partly due to a shared 
common receptor transmembrane subunit, interleukin-4-receptor alpha (IL-4Rα), in their 

















IL-4 receptor is a type I transmembrane protein that can bind both IL-4 and IL-13 and has 
various functions.  The IL-4Rα on T cells binds IL-4 promoting differentiation of Th2 cells. 
Allelic variations in this gene have been associated with many allergic conditions such as 
atopy, asthma, eczema and, sinusitis.
116 
It is also important for the inhibition of Th1-
associated pro-inflammatory cytokines such as IFNγ and TNF. 
118 
Mice treated with anti-IL-
4Rα antibodies specifically blocked responses of IL-4 signalling. 
119-122 
The IL-4Rα consists 
of a 140-kDa IL-4Rα chain and is a component of both the type I and type II IL-4 receptors. 
It is expressed in relatively low numbers on numerous cell types. 
124, 125  
The type I IL-4 
receptor is a combination of IL-4Rα with the common γ-chain (γc) of cytokine receptors, 




IL-4Rα subunit paired with the 65-70kDa IL-13Rα1 chain forms a complex known 
as type II IL-4Rα or IL-13 receptor, through which both IL-4 and IL-13 can signal. The IL-
13Rα1 has a low binding affinity to IL-13 but when paired with IL-4Rα, it has a high affinity 
for IL-13. IL-4 signalling can occur through both type I and type II receptors whereas IL-13 
only binds to type 2 receptors. 
126,127 
IL-13Rα1 is expressed on many cell types including- B 
cells, basophils, endothelial cells, macrophages, mast cells and monocytes.
126, 128,129
 
Although IL-13 signals via the IL-13Rα1, studies have shown that IL-13 has a higher binding 
affinity to the α2 chain of the IL-13 recept r (IL-13Rα2) and can signal through it.
130  
IL-
13Rα2 is a 55-60 kDa protein closely related to IL-13Rα1 except that the cytoplasmic domain 
has no signalling motifs or binding sequences for signalling molecules.
131, 132 
In addition to 
the cell surface receptors, soluble forms of both IL-4Rα and IL-13Rα2 exist. These are 
suggested to bind IL-4 and IL-13 with high affinity as non-signalling monomers. Therefore, 
the soluble receptors can act as competitive inhibitors of IL-4 and IL-13 regulating their 
activity.
133, 134  
 
IL-4Rα brings together receptor associated Janus Kinases (JAKs) upon binding of IL-4 to IL-
4Rα or binding of IL-13 to IL-4Rα/IL-13Rα1 complex as shown in figure 1.4. JAK-
dependent tyrosine phosphorylation of the IL-4Rα results in phosphorylation of the 
transcription factor known as signal transducer and activator of transcription 6 (STAT 6) 
enabling the transcription of many Th2 associated genes by translocation to the nucleus.
135,136 
Other signalling intermediates like Insulin like receptor substrate (IRS) family can also be 
phosphorylated by IL-4Rα. This common signalling pathway favours the sharing of many 















alternate macrophage activation, inhibition of inflammatory macrophage products, 
upregulation of MHC class II and promotion of Th2 type responses.
113, 115, 137 
Different 




IL-4 and IL-13 are predominantly produced by basophils, mast cells and activated CD4
+
 Th2 
cells. Inspite of common functions, these two cytokines have distinct functions because of the 
expression of various receptor components on different cell types. T cells do not express type 
II IL-4 receptor (IL-13Rα1) and hence cannot respond to IL-13. This indicates the 
dependency of Th2 cell differentiation on IL-4 but not IL-13 signals. Human and mouse B 
cells respond differently to IL-13 for IgE class switch. Type I and type II IL-4 receptors are 
widely expressed in different cell types and tissues. A high affinity receptor for IL-13 is IL-
13Rα2 which exists in membrane bound and soluble forms. Due to the lack in function of 
intracellular signalling, IL-13Rα2 has been reported as a decoy receptor which also inhibits 
IL-13 dependent symptoms in experimental asthma providing a negative feedback 






















Figure 4. IL-4, IL-13 cytokines, their receptor complexes and general signalling 
pathways. The IL-4 cytokine can bind to a type I (left) or Type II (middle) receptor, while 
IL-13 can bind to the Type II (middle) heterodimeric receptor or IL-13Rα2 (right). The IL-
4Rα subunit is shared in both receptor types and associates with either JAK which activates 






















1.4.2 IL-4Rα in allergies and asthma 
 
Allergen specific Th2 cells inducing symptoms of allergic airway disease have been 
reported.
143, 144 
Studies have shown that CD4
+
 T cells are necessary for the development of 
AHR and airway eosinophilia.
19 
The key cells contributing to the onset and pathogenesis of 
asthma include T cells, B cells, epithelial cells and smooth muscle cells all of which express 
functional IL-4Rα .  
 
Experimental models in which IL-4Rα was blocked, showed impairment in the development 
of AHR and airway eosinophilia.
145, 146 
Mice deficient in IL-4Rα lack allergen specific IgE 
production, eosinophilic airway inflammation and goblet cell hyperplasia and have abrogated 
Th2 type responses.
75, 147 
IL-4Rα have also shown antigen specific 
Th1 type cytokine and antibody responses and airway inflammation characterised by an 
increase in number of neutrophils. Other studies using gene deficient mice have shown that 
the development of AHR and specific IgE is IL-5 and IL-13 dependent.
148
 Development of 
IgE and allergic responses after prolonged sensitization in IL-4Rα
-/- 
has also been 
demonstrated. 
149, 150 
Our laboratory has also shown that IL-4Rα on smooth muscle cells is 
not required for the development of experimental allergic asthma.
151 
However, IL-4Rα 
signalling on smooth muscle cells can contribute to disease.IL-4 and IL-13 responsiveness 
may also contribute to the development of a Th2 type immune response.
152, 153 
IL-4 and IL-13 
signalling through IL-4Rα induces the development of alternatively activated macrophages.
87  
 
IL-4, IL-13 and their receptors are potential drug targets for allergic asthma as the pathology 
of the disease involves these IL-4Rα expressing cells. Although the use of anti IL-4 
monoclonal antibodies was not effective at preventing asthma, the use of soluble IL-4Rα 
antagonists did show some convincing results.
154, 155  
Clinical studies have also established 
that Single Nucleotide Polymorphisms (SNPs) in IL4Ralpha are associated with severe 
asthma exacerbations, lower lung function, and increased mast cell-related tissue 
inflammation. 
156 
Furthermore, another clinical study has investigated the conservative region 
of IL-4Rα in human susceptibility to allergic asthma, highlighting the importance of IL-4Rα 

















Thus IL-4Rα signalling seem to be essential for the development of Th2 cells in allergic 
airway disease but the contribution of IL-4Rα dependent Th2 cells (or: IL-4 and IL-13 
responsive Th2 cells) to the disease development yet to be characterised. 
 
1.4.3 Cell specific knockout mice and IL-4Rα knockout mouse models 
  
The Cre recombinase-loxP (Cre-loxP) system has led to the development of several 
transgenic strains of mice that enable the investigation of cell specific gene function in vivo. 
158-160. 
This system utilises enzymes and DNA sequences derived from bacteriophage P1, 
which uses them to excise itself from the host cell. Integration of bacteriophage P1 DNA into 
the genome of the host cell results in flanking of the targeted gene promoter by loxP sites, 
which are recognised by the enzyme Cre recombinase. Introduction of loxP sites on either 
side of a gene or exon in the mouse favour the excision of these specific genes or exons, 
resulting in cell specific deletion. Mice containing loxP sites flanking a specific gene or 
exons are mated with transgenic mice that express Cre recombinase under the control of 
promoter of the type of cell or tissue of interest. Thus the active Cre-recombinase in the 
appropriate tissue will excise the DNA between the inserted loxP sites effectively inactivating 
the targeted gene. Cells lacking the expression of the Cre- recombinase promoter will not 
excise the gene thus resulting in a tissue specific knockout mouse.
161 
 
Using the Cre-loxP system as illustrated in figure 5, our laboratory and others have generated 
mice with cell-specific IL-4Rα deletion (exon 7-9) in several different cell types, for 




, dendritic cells and 
alveolar macrophages, lung (Clara) cells 
82
,  macrophages and neutrophils 
165,166
, B cells and 
smooth muscle cells 
151,167





, intracellular parasite and helminth infections 
162,167
 unravelling 
the importance of Th2 and hence IL-4Rα-dependent mechanisms in these cell lineages. The 
first experimental study to demonstrate that IL-4Rα  cell type was 
sufficient for the development of a major symptom of allergic airway disease was performed 





Generation of transgenic mice with cell type specific disruptions in the IL-4Rα gene are an 















in allergic airway disease. Although the general importance of the IL-4Rα 
development is well established, its cell type specific functions often remain elusive. To date 
the cell specific role of IL-4Rα in allergy has only been described in vivo for epithelial cells 
and smooth muscle cells. Disrupted IL-4Rα signalling on epithelial cells resulted in 
protection from airway mucus production but not airway inflammation or hyperreactivity 
82 
whereas the impairment of IL-4Rα on smooth muscle cells in early stages of AAD did not 




However it is quite crucial to determine the cell specific effects of cytokine signalling so that 
the pathways important for the elicitation of AAD could be defined. This would eventually 


























Figure 5. Breeding strategy for generation of cell specific IL-4Rα knockout mice. Mice 
heterozygous for a floxed and deleted IL-4Rα allele were crossed with mice harboring the 
Cre-recombinase gene under the control of a cell specific promoter. The Cre, expressed only 
in the desired cell type, recognizes the floxed sequence and excises the portion of the gene in 
between resulting in a cell specific deletion of the IL-4Rα gene. Using a heterozygous mouse 
increases the efficiency of deletion by reducing the substrate for the Cre-recombinase by half. 
The insert in the figure shows the IL-4Rα gene and restriction enzyme sites are labelled E, B 





























Using the principles described above in Figure 5, mice with a specific deletion of IL-4Rα on 
CD4
+
 T cells have been generated.
164
 An IL-4Rα 
-/-
  mouse was crossed with a transgenic 
mouse expressing Cre recombinase under control of the T-cell specific promoter, lymphocyte 
specific tyrosine kinase (Lck
cre









mouse was crossed with a mouse bearing two loxed IL-4Rα alleles (lox/lox) in 




offspring.  IL-4Rα hemizygosity (
-lox
) increases the 











mice were back crossed to BALB/c wild types 










 mouse strain, characterized by complete deletion of IL-4Rα on CD4
+
 T 
showed  incomplete deletion efficiency on CD8
+
and NK T cells and normal IL-4Rα 
expression on CD4
-
 T cells. 
  
These mice have impaired IL-4-induced CD4
+
 proliferation and 







 mice were found to be protected against anaphylaxis in a manner 
that was dependent upon their increased production of IFN-gamma.
 163 
They were also 
protected against Leishmania major infection 
164
, had increased survival after infection with 
Schistosoma mansoni
169 







 mice showed reduced lung pathology after Nippostrongylus brasiliensis 
infection, with decreased mucus secretion, lymphocytes and eosinophils in the lungs.
162 
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mouse was crossed with a mouse bearing two loxed IL-4Rα alleles 




offspring.  IL-4Rα hemizygosity (
-lox
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mice were back crossed to 
















Genes under the macrophage- and neutrophil-specific lysozyme M (LysM) promoter 
171
 have 









) function in macrophage/neutrophil lineages in helminth infections 
162,167











 mice were generated as shown in 













 mice were mated with 





 offspring. These offspring were mated with mice containing IL-4Rα 
flanked by loxP sites (IL-4Rα
lox/lox
























1.5 Thesis Objectives 
 
The aim of this study is to investigate the cell specific contributions of IL-4Rα signalling in 
the development of Ovalbumin-induced chronic allergic airway disease (AAD) in mice. 
 
Specifically, we aim to investigate the following: 
 
Firstly, the role of IL-4/IL-13 responsive CD4
+ 
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IL-4Rα expression on CD4
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 T cells is required for 
















2 IL-4Rα expression on CD4
+
 T cells is required for chronic 





To date the cell specific role of IL-4Rα in AAD has only been described in vivo for epithelial 
cells and smooth muscle cells. Disrupted epithelial IL-4Rα signalling resulted in decreased 
airway mucus production but did not affect airway inflammation or hyperreactivity. This 
study was conducted to investigate how IL-4Rα signalling on CD4
+
 T cells influences the 




 mice deficient for IL-4Rα on 
CD4
+
 T cells, the in vivo effects of impaired IL-4Rα signalling on CD4
+
 T cells on the 
outcome of AAD could be investigated. 
 
Objective 







AAD was introduced in mice by subcutaneous sensitisation with 20 µg ovalbumin (OVA) 
adsorbed to 0.65% alum on days 0, 7, 14, and 21. On days 27 and 29 and then twice weekly 
for 4 weeks, mice were challenged intranasally with 20 µg OVA in 50 µL PBS under 
anaesthesia. Mice were investigated for the presence of airway hyperresponsiveness (AHR), 









were significantly protected. Airway hyperreactivity, Th2 responses, mucus hypersecretion, 
eosinophil infiltration, and collagen deposition were decreased in comparison to IL-4Rα
-/lox 



















These findings demonstrate that IL-4Rα signalling through CD4
+
 T cells is critical for the 




Allergic asthma is characterised by inflammatory responses to inhaled allergens orchestrated 
by CD4
+
 T cells which produce a characteristic Th2 cytokine profile causing eosinophilic 
lung inflammation. 
1 
Thus Th2 responses drive chronic allergic lung inflammation in 
asthmatic patients after allergen challenge by elevated numbers of CD4
+
 T cells and Th2 
cytokines in bronchoalveolar lavage (BAL) specimens.
2
 Airway remodelling, a characteristic 
of chronic asthma is a consequence of unresolved airway inflammation that results in 
irreversible permanent structural changes in the airways. The structural changes include: 
increased airway wall thickness involving smooth muscle and collagen tissue, subepithelial 
fibrosis and hyperplasia of myofibroblasts and goblet cells 
3, 4, 5
 leading to increased mucus 
production and increased vascularity in the airways contributing to sustained AHR. 
6,7,8
 These 
structural changes lead to reduced lung function in asthmatic patients and airway biopsies 
from these patients suggest that the disease severity 
9 
and AHR is related to both the degree of 
smooth muscle thickness and the extent of subepithelial fibrosis and magnitude of AHR.
10, 11 
In patients with atopic asthma, allergen inhalation challenge lead to activation of CD4
+
 T 
cells and increases Th2-type cytokine mRNA expression, which is thought to contribute to 




Murine models of acute AAD have shown that CD4
+
 T cells are required for eosinophilic 
lung inflammation and airway hyperresponsiveness, and adoptively transferred CD4
+ 
T cells 
can induce these features. 
13, 14
 In mice, CD4
+
 T cells contribute to the pathology similar to 




murine models have also 
shown that Th2 cytokines which are produced as a result of CD4
+
 T cells can induce AHR at 
an early stage without a requirement for inflammatory cell recruitment.
16 
It has also been 
established that Th2-induced airway mucus production is dependent on IL-4Rα, but not on 
eosinophils.
17  
However, therapies targeting either CD4
+















and IL-5 have not been successful. 
18-20 
The mechanisms through which CD4
+
 T cells 
contribute to chronic asthma pathogenesis remains poorly understood.  
 
In acute murine models of AAD, CD4
+
 T cell depletion reduced inflammation and airway 
remodelling. 
21, 22
 Furthermore, adoptively transferred CD4
+
 T cells from ovalbumin (OVA)-
sensitized rats induced increases in airway smooth muscle mass after repetitive challenge 




 T cells appear to be required for both initiation of 
airway inflammation and induction of remodeling. CD4 depletion three weeks after the 
termination of chronic antigen challenge was found to have no effect on features of airway 
remodeling. 
24
 Even though still underwent the process of lung remodelling, CD4
+
 T cell 







 mouse strain is characterized by complete deletion of IL-4Rα on CD4
+
 
T cells, incomplete deletion efficiency in CD8
+
and NK T cells and normal IL-4Rα expression 
on γδ
+
 T cells. 
26
 These mice have impaired IL-4-induced CD4
+
 proliferation and Th2 
differentiation, but normal IL-4 and/or IL-13 responsiveness by other T cells and non-T cells. 
26, 27









 mice were found to be protected against 
anaphylaxis in a manner that was dependent upon their increased production of IFN-
gamma.
28 
They were also protected against Leishmania major infection, 
26
 had increased 
survival after infection with Schistosoma mansoni 
29
 and were protected in oxazolone-






 mice showed reduced lung pathology after 
Nippostrongylus brasiliensis infection, with decreased mucus secretion, lymphocytes and 
eosinophils in the lungs. 
31 
 




mice in a short-term model of acute allergic airway 
disease (AAD) 
32, 33 
was previously examined by another researcher in our laboratory.
 
Despite 
all the evidence of the significance of Th2 in asthma, interestingly LckcreIL-4Rα-/lox mice 
maintained susceptibility to AAD in the acute model, with comparable airway 
hyperreactivity, airway resistance and elastance to IL-4Rα-/lox littermate control mice. 
34
 







 x IL-13 
-/-





 x IL-4 
-/-
 did not . Importantly this indicates a role for IL-4 independent Th2 















on CD4+ T cells and airway remodelling in a chronic model. The role of IL-4 independent 
Th2 in allergic airway disease is of interest, and may explain why IL-4 neutralization does 
not work well as a therapy for asthma.  
 
Therefore, we aimed to determine whether IL-4Rα dependent CD4
+ 
T cells contribute to 
ovalbumin induced AAD in a chronic model, and to examine the effect of CD4
+
 T cell 





 mice in acute AAD, our studies using the long-term chronic model of AAD 




 mice were significantly protected, showing decreased 
airway hyperreactivity, airway resistance, and airway elastance, as well as decreased numbers 
and percentages of eosinophils in the bronchiolar lavage fluid and lungs and decreased lung 
inflammation, mucus hypersecretion and airway remodelling compared to IL-4Rα
-/lox 
littermate controls. Our results demonstrate significant reduction in AAD in the absence of 
IL-4Rα dependent CD4
+
 T cells in the chronic model, suggesting that IL-4Rα dependent 
CD4
+
 T cells may be critical in sustaining AAD in mice showing that IL-4Rα signalling 
through CD4
+































2.3 Materials and Methods 
Mice 










 female mice 
35
 on a 
BALB/c background were housed in independently ventilated cages under specific pathogen-
free conditions in the University of Cape Town Animal Facility. Animal procedures were 
approved by the University of Cape Town Animal Ethics Committee. (Permit Number: 
008/016) 
Generation of IL-4Rα knockout mice 
The generation and characterization of CD4
+ 



























 mice were generated by mating floxed IL-4Rα
lox/lox
 mice with transgenic 
Lck
cre
 mice.  These mice were then back-crossed to the BALB/c background for 9 
generations prior to crossing with global IL-4Rα knockout (IL-4Ra
-/-





 BALB/c mice. BALB/c (IL-4Rα
+/+





 mice were used as controls in all experiments. 
 
Genotyping of IL-4Rα knockout mice 
Mice were genotyped by PCR to determine what IL-4Rα allele was present and the PCR 
conditions were as follows: 94°C/30 s; 57°C/30 s, 72°C/1 min for 40 cycles on an MJ 
thermocycler (Biozym, Hessisch, Oldendorf, Germany). 
Primers used for PCR screening of the mice: 
 
oLCK Cre Transgene allele 
Cre LCK R:   5’- CAG GTA TGC TCA GAA AAC GCC TGG -3’ 
Prox LCKpF:   5’- GAG GGT GGA ATG AAA CTC TCG GT -3’ 
 
IL-4R Wildtype allele 
Exon 7 forward1:     5’-TGA CCT ACA AGG AAC CCA GGC-3’  
Exon 8 reverse: 5’-CTC GGC GCA CTG ACC CAT CT-3’  
 
IL-4R Deleted allele 
IL-4Rα KO P1:  5’ - GGC TGC TGA CCT GGA ATA ACC - 3’   
















Conditional IL-4R LoxP allele 
IL-4Rα KO P1: 5’ - GGC TGC TGA CCT GGA ATA ACC - 3’  
IL-4R Intron 6-Rev: 5’ – GTT TCC TCC TAC CGC TGA TT – 3’ 
 
Sensitisation and challenge of mice  
Mice were sensitized subcutaneously with 200 µl (20 µg ovalbumin (OVA) adsorbed to 
0.65% alum) on days 0, 7, 14, and 21. On days 27 and 29 and then twice weekly for 4 weeks, 





Measurement of Airway Hyperreactivity 
Airway resistance and elastance of the whole respiratory system (airways, lung chest wall) 
after challenge with increasing doses of acetyl-b-methylcholine (methacholine, Sigma-
Aldrich, Aston Manor, South Africa) were determined by forced oscillation measurements as  
described 
36
 with a Flexivent system (SCIREQ, Montreal, Canada) by using the 
singlecompartment (‘‘snapshot’’) perturbation. Differences in the dose-response curves were 
analyzed by repeated-measures ANOVA. Only mice with acceptable measurements for all 
doses (coefficient of determination >0.95) were included in the analysis.  
 
Flow cytometry 
Bronchoalveolar lavage (BAL) cells were obtained by flushing the lungs of sacrificed mice 
once with 1 mL PBS/10% FCS. 
 
Single-cell suspensions were prepared from lungs after digestion for 1 hour at 37°C in 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Invitrogen, Carlsbad, Calif) containing 13 
mg/mL DNase I (Roche, Randburg, South Africa) and 50 U/mL collagenase IV (Sigma-
Aldrich, Aston Manor, South Africa).  
 
For intracellular cytokine staining, lung cells were incubated at 37°C for 4 hours with phorbal 
myristate acetate (Sigma-Aldrich) (50 ng/mL), ionomycin (Sigma-Aldrich) (250 ng/mL), and 
monensin (Sigma-Aldrich) (200 mM in IMDM/10% FCS). Cells were stained with CD3-
fluorescein isothiocyanate (clone 145-2C11) and CD4-PerCP (clone L3T4) (BD Bioscience), 
and intracellular cytokines were stained with anti–IL-4 (clone 11B11), anti–IL-5 (clone 















anti–IL-13 (clone eBio 13A) (eBioscience, San Diego, Calif), and rat anti-mouse IgG1 
isotype control (clone A85-1) (BD Bioscience) (all PE-labeled). Cells were acquired on a 
FACSCalibur machine (BD Immunocytometry Systems, San Jose, Calif), and data were 
analyzed by using Flowjo software (Treestar, Ashland, Ore). 
 
For flow cytometry, the following antibodies were used: SiglecF-PE (clone E50-2440), 
CD11c-APC (clone HL3), CD4-PerCP (clone L3T4), with streptavidin (all BD Bioscience, 
Erembodegem, Belgium), CD3 FITC fluorescein isothiocyanate (clone 145-2C11) and GR-1-
fluorescein isothiocyanate (clone RB68C5). 
  
Sorting of alveolar macrophages 




 cells from the pooled lungs of OVA-
sensitized and -challenged mice. Cells were sorted on a FACSVantage flow cytometer (BD 
Immunocytometry Systems, San Jose, Calif). Purity was determined by flow cytometry and 
checked by cytospin and staining with the Rapidiff Stain set (Clinical Diagnostics CC, 
Southdale, South Africa) and was at least 99%. 
 
RNA extraction, cDNA synthesis and Quantitative RT-PCR 
Total RNA was extracted from sorted alveolar macrophages of >98% purity by using Tri 
reagent (Applied Biosystems, Carlsbad, Calif) according to the manufacturer’s protocol and 
purified with RNeasy Microprep kit (Qiagen Hilden, Germany).  
Sorted alveolar macrophages were lysed in 500 µl TriReagent® (Molecular Research, USA) 
and stored at -80 °C. To extract the RNA, thawed samples were incubated at room 
temperature for 5 min to ensure complete dissociation of nucleoproteins. To each sample, 0.1 
ml of chloroform was added and samples were vortexed for 15 seconds and incubated at 
room temperature for a further 15 min prior to centrifugation at 12000 rpm for 15 min at 4°C. 
The RNA contained in the upper aqueous layer was purified using the miRNeasy Mini Kit 
(Cat. No. 217004, Qiagen, USA), RNeasy MinElute Cleanup Kit (Cat. No. 74204, Qiagen, 
USA) and the RNase-Free DNase Set (Cat. No. 79254, Qiagen, USA). RNA quantity was 
determined using a Nanodrop ND1000 (Thermo Scientific, USA). 
cDNA was synthesized with Transcriptor First Strand cDNA synthesis kit (Roche). Real-time 
quantitative PCR was performed on cDNA samples to determine gene expression levels of 
marker genes by using Lightcycler FastStart DNA MasterPLUS SYBR Green I reaction mix 















(Cat. No. 04913850001, Roche, Germany), primers and cDNA template. Reactions were 
prepared in 96- well plates (Roche, Germany) and PCRs were performed in a LightCycler® 
480 (Roche, Germany). 
 
Primers for inducible nitric oxide synthase (iNOS), arginase, Ym-1, and FIZZ-1 have been 
previously described and are listed in Table 2.1 
37, 39, 40
   Gene expression levels were 
normalized according to the expression of the housekeeping genes ribosomal rs12 or HPRT. 
 
 
Table 2.1: RT-PCR primers and PCR conditions 
 




















































Histology and immunohistochemistry 
Lungs were fixed in 4% formaldehyde/PBS and embedded in paraffin. Tissue sections were 
stained with haemotoxylin and eosin (H&E), periodic acid-Schiff (PAS) for mucus, Sirius red 
for collagen, Martius scarlet blue (MSB) for fibrin and Gordon and Sweets for reticulin 
(reticulin silver staining kit). Image analysis was performed on NIS Elements (Nikon 
Instruments, Tokyo, Japan). Lung sections from individual mice were assessed, and data from 

















Blood samples taken by tail vein bleeding or directly from mice after sacrificing were 
collected in plasma separator tubes (MicrotainerTM SST, BD, USA). Samples were 
centrifuged for 20min at 6000rcf and stored at -80ºC. OVA specific antibodies were 
measured in blood serum by endpoint titration ELISA. For OVA specific antibodies, 96 well 
ELISA plates (Maxisorp, Nunc, Denmark) were coated overnight with 50µl OVA in PBS 
(5µg/ml for IgG1, IgG2a, IgG2b or 1mg/ml for IgE). For total IgE ELISA, plates were coated 
with anti-mouse IgE antibody (clone 84.1C, 1/1000 dilution). Plates were blocked for 1h at 
37ºC with 200µl 2% fat free milk powder in PBS. Serial dilutions of serum samples in 50µl 
PBS/ 0.1% BSA were added to the wells and plates were incubated overnight at 4 ºC. 
Purified recombinant mouse IgE (BD, USA) was used as a standard for total IgE ELISA, at a 
starting concentration of 1mg/ml. 50µl alkaline phosphatase conjugated goat anti-mouse 
isotype specific antibodies (Southern Biotechnology, USA) at a 1/1000 dilution in PBS/ 0.1% 
BSA were added to the wells and the plates were incubated for 3h at 37ºC. Subsequently, 
plates were incubated with 50µl pnitrophenylphosphate (Fluka, Switzerland) and the colour 
reaction was stopped with 50µl 1M NaOH. Absorption was measured at 405nm with 492nm 
as reference wave length using a VersaMax plate reader (Molecular devices,USA). Plates 
were washed 4x with 200µl per well after each incubation step. 
 
Statistical analysis 
P values were calculated in GraphPad Prism 4 (GraphPad Software, Inc, San Diego, Calif) by 
using ANOVA with Bonferroni’s posttest or repeated measures ANOVA, and results are 























 mice are protected against the development of AHR 
 




 mice and littermate controls were examined in 
OVA-induced allergic airway disease. Airway resistance (R) and elastance (E) were 
measured in response to increasing doses of methacholine after chronic exposure to OVA. 
Airway dynamic resistance (R) quantitatively assesses the level of constriction in the lungs. 
Increased R values signal constriction of the lungs and this parameter reflects not only central 
airway resistance, but is also influenced by the lung periphery (the "tissues").Dynamic 
elastance  (E) captures the elastic rigidity of the lungs and reflects the mechanical properties 
of the lungs for normal respiratory rates. Increased E values signal an increased stiffness of 
the lungs.  
 
The OVA sensitised and challenged mice developed AHR, with significant differences 
between IL-4Rα
-/lox




 mice (Fig.1 A, B). A 





 mice compared to littermate control mice. Global IL-4Rα
-/-
 mice did not 
show a significant increase in AHR compared with saline controls, demonstrating protection. 
Since airway resistance assesses constriction of the airways, an increase in E values may 
indicate similar airway remodeling in littermate controls. These results provide strong 
evidence that the absence of IL-4Rα dependent CD4
+ 
























 OVA mice are protected against AHR. Airway Resistance (A) 




 OVA mice compared to 
IL-4Rα
-/lox
 PBS mice and IL-4Rα
-/lox
 OVA mice. N= 10-16 mice, pooled data from three 
individual experiments.  Significant differences between IL-4R
-/lox





mice are represented by stars (*, P<0.05, **, P<0.01), ***, P<0.001) and significant 
differences between IL-4R-
/lox
 OVA and Lck
cre
 IL-4R-
/lox mice are represented by hashes (#, 
P<0.05, ###, P<0.001). P values are in comparison to individual responses and different 





















As a consequence of OVA sensitisation and challenge, inflammatory cells are recruited to the 





sensitised and challenged with OVA had decreased percentage of eosinophils similar to PBS 
controls and decreased in comparison with IL-4Rα
-/lox
 littermate control mice sensitised and 
challenged with OVA (Fig 2A). The global knockout mice IL-4Rα
-/- 
OVA sensitised and 
challenged with OVA had also decreased percentage of eosinophils compared to IL-4Rα
-/lox
 




 mice was 
decreased same as in all mice groups except for IL-4Rα
-/-
 mice sensitised and challenged with 
OVA where it was increased. IL-4Rα
-/lox 
OVA mice had increased mucus hypersecretion 
(quantified by image Analysis on NIS Elements software) compared with PBS controls, but 
mucus hypersecretion was abrogated in the global IL-4Rα
-/-
 strain (Fig 2B).  
 




 OVA mice (Fig 3L) was 
decreased and similar to IL-4Rα
-/lox
 PBS mice (Fig 3I), IL-4Rα
-/-
 OVA mice (Fig 3K) 
compared to IL-4Rα
-/lox
 OVA mice (Fig 3J). Our data illustrate that IL-4Rα dependent CD4
+
 
T cells are necessary for the development of OVA-induced allergic airway inflammation and 














































 mice sensitised and 
challenged with OVA compared to IL-4Rα
-/lox
 mice sensitised and challenged with OVA. 







 mice sensitised and challenged with OVA mice Significance was to 
IL-4Rα
-/lox
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Figure 3. Airway infiltration of the lung tissue with inflammatory cells, goblet cell 
hyperplasia and collagen deposition is affected by loss of IL-4Rα on CD4
+
 T cells. Lung 
sections from IL-4Rα
-/lox
 mice sensitised and challenged with saline /PBS (A) and OVA 
sensitised and challenged  littermate control IL-4Rα
-/lox
 mice (B), IL-4Rα
-/-





 mice (D) were stained with H&E. Mucus hyper secretion by goblet cells 
were stained with PAS in the airways of  PBS sensitised and challenged IL-4Rα
-/lox
 mice (E) 
and OVA sensitised and challenged  littermate control IL-4Rα
-/lox







 mice (H). Collagen deposition around airways and blood vessels 
were illustrated by Sirius red staining in IL-4Rα
-/lox
 mice sensitised and challenged with 
saline /PBS (I) and OVA sensitised and challenged  littermate control IL-4Rα-/lox mice (J), 
IL-4Rα
-/-






















Figure 4. Airway remodelling is affected by loss of IL-4Rα on CD4
+
 T cells. Lung 
sections from IL-4Rα
-/lox
 mice sensitised and challenged with saline /PBS (A) and OVA 
sensitised and challenged littermate control IL-4Rα
-/lox
 mice (B), IL-4Rα
-/-





 mice (D) were stained with Martius scarlet blue. Increased fibrin threads 
(stained red) were observed in the airways of OVA sensitised and challenged IL-4Rα
-/lox
 mice 




 mice (D). Epithelial 
thickness and subepithelial collagen deposition were illustrated by reticulin fibre staining. 
OVA sensitised and challenged littermate control IL-4Rα
-/lox
 mice (F) showed loose arrays of 
reticular fibres (stained black) around the alveolar walls and increased collagen deposition (in 




















The infiltration of inflammatory cells in the lung tissue around airways and blood vessels is a 
characteristic of allergic airway disease. During chronic allergic airway disease, H&E 
staining showed no infiltration of inflammatory cells around the airways in littermate control 
mice sensitised and challenged with PBS (Fig 3A). IL-4Rα
-/lox 
mice sensitised and challenged 
with OVA showed severe infiltration of inflammatory cells around the airways (Fig 3B).  
There was a reduction in inflammation observed both in IL-4Rα
-/-





 OVA mice (Fig. 3D).  
 
Mucus hypersecretion by goblet cells is a characteristic of AAD. Histological examination of 
lungs stained with PAS showed no signs of mucus hypersecretion in the airways of PBS 
sensitised and challenged IL-4Rα
-/lox
 mice (Fig. 3E) compared to IL-4Rα
-/lox
 OVA mice (Fig. 
3F) which showed mucus hyper secretion indicating the severity of goblet cell hyperplasia. 
IL-4Rα
-/-










Sirius red staining showed little collagen deposition around airways and blood vessels in 
mice sensitised and challenged with PBS (Fig. 3I) compared to the IL-4Rα
-/lox
 OVA mice 




 mice (Fig. 
3K) and IL-4Rα
-/-
 mice (Fig.3L) showed little collagen deposition around airways and blood 
vessels. 
 
Fibrin deposition occurs as a result of inflammatory reactions in AAD. Martius Scarlet blue 
staining showed increased fibrin mass around the airways of OVA sensitised and challenged 
IL-4Rα
-/lox
 littermate control mice (Fig. 4B) compared to IL-4Rα
-/lox
 PBS mice (Fig. 4A) . IL-
4Rα
-/-




 OVA mice 
revealed few fibrin threads around the airways (Fig. 4D) compared to IL-4Rα
-/lox
 OVA mice. 
In chronic AAD, airway remodelling includes structural changes such as epithelial shedding 
and increased subepithelial collagen deposition. Reticulin silver staining showed increased 
thickness of basement membrane and loose arrays of reticulin fibres in the airways of OVA 
sensitised and challenged IL-4Rα
-/lox
 littermate control mice (Fig. 4F) compared to IL-4Rα
-/lox
 
PBS mice (Fig. 4E) . IL-4Rα
-/-




 OVA mice showed thick array of 























In order to investigate if the antibody responses to chronic OVA sensitisation and challenge 
are affected by IL-4Rα signalling on CD4
+











A higher serum IgG1 was observed in Lck
cre
IL-4Rα
-/lox OVA mice compared to IL-4Rα-/lox 








mice also showed a 





 PBS and OVA mice also showed lower IgG2a and 
IgG2b. As expected, IL-4Rα
-/-
 mice showed significantly increased levels of specific IgG2a 





mice are similar to the littermate control OVA mice.  
 





mice compared to IL-4Rα
-/lox
 OVA mice. (Fig 6A) Total IgE 






mice compared to 
littermate control mice. (Fig 6B)  
 





























 mice are similar to IL-
4Rα
-/lox
 littermate control mice and indicate a predominantly Th2-type response. OVA 
specific antibodies were measured by end point titration ELISA. IgG1 (A), IgG2a (B), IgG2b 


































OVA specific IgE (A) and total IgE 
(B) antibodies were measured by ELISA. (ND Non Detectable) Significant differences 
between IL-4R
-/lox




mice are represented by stars (***, P<0.001) 
and significant differences between IL-4R-
/lox
 OVA and Lck
cre
 IL-4R-
/lox mice are 



















Figure 7.  Sensitisation and challenge with OVA induces a Th2 type immune response in 
IL-4Rα
-/lox




 mice. Lung cells were incubated at 37°C for 4 
hours with phorbal myristate acetate (PMA), ionomycin and monensin for intracellular 
cytokine staining. N=5-8 mice, pooled data from two individual experiments. Significant 
differences to IL-4Rα
-/lox
















The percentages of IL-4, IL-5 and IL-13 producing CD4
+





mice sensitised and challenged
 








mice showed significant percentage 
increases of IL-4, IL-5 and IL-13 producing CD4
+
 T cells compared with PBS littermate 
controls. The percentage of IL-17 producing CD4
+







mice sensitised and challenged
 
with OVA (Fig 7). Hence our 
results confirm that the absence of IL-4Rα on CD4
+
 T cells did suppress Th2 and Th17 





















Figure 8. mRNA expression in alveolar macrophages normalized with rs12 
housekeeping gene. Expression of Ym-1(A), Fizz-1(B), arginase(C) and iNOS(D) 




 mice compared to IL-4Rα
-/lox 
OVA mice. Data 






















Alveolar macrophages from OVA sensitised and challenged mice were sorted. mRNA 
expression of markers for classical activation (iNOS) and alternative activation (Ym-1, FIZZ-
1, and Arg-1) was quantified using RT-PCR, using the rs12 housekeeping gene for 
normalisation. IL-4Rα
-/lox
 mice showed alternative activation of macrophages as there was 
increased expression of Ym-1, FIZZ-1, and arginase in comparison to saline controls. (Fig. 8 





 mice compared to IL-4Rα
-/lox
 mice showing that in the 
absence of IL-4Rα signalling on CD4
+ 
T cells, there is reduced classical and alternative 














































 Studies exploring T cell therapies have been conducted over two decades ago 
but without any convincing results.
42 
The blocking of T cells in asthmatic patients showed 
some improvement in pathology of asthmatics.
43
 But the use of anti-CD4 monoclonal 
antibody did not reduce the symptoms of asthma. 
44, 45
 Th2 cytokine blocking Therapies 
involving anti-cytokine agents were introduced to curb inflammation in asthma. Studies 
conducted in human, aimed to target the main Th2 cytokines including IL-4, IL-5, IL-9 and 
IL-13. IL-4 blockade in mouse models of asthma showed abrogated pathology in asthma.
 46
 
Some promising evidence has been shown by the administration of solubilised IL-4 receptor 
fragment in treating asthma. 
47
 Clinical trials have shown the lack of efficacy of the soluble 
IL-4 receptor and anti-IL-4 humanised monoclonal antibody. 
48, 49
 The key role of IL-5 and 
use of IL-5 antibody in asthma pathology have been demonstrated by studies conducted in 
murine and guinea pig models. 
50-53
 Human studies involving administration of human IL-5 
antibody also failed to show prevention of asthmatic symptoms. 
54-56
 In mouse models of 
asthma, blocking IL-9 by antagonists reduced allergen-induced airway inflammation and 
AHR. The use of anti-IL-13 monoclonal antibodies and soluble IL-13 receptor showed 
reduced inflammation in asthma.
57-59
 In vitro and humanised animal studies using IL-13-




Lung biopsies and respiratory secretions from asthmatic patients have demonstrated that 
CD4
+
 T cell infiltration around the airways and eosinophil recruitment are key events of the 
inflammatory process contributing to disease severity.
61-63 
Murine models have demonstrated 
that CD4
+
 T cells and IL-5 secretion by these cells, in conjunction with eosinophil 
recruitment at inflammatory sites, contribute to the  pathophysiology of allergic airways 
inflammation.
14 





T cells contribute to eosinophilic lung inflammation , they are not required for 
subsequent airway remodeling.
14 
In murine T cells, IL-4 mediates multiple effects. In addition 
these cells do not respond to IL-1 which plays a role in immune and inflammatory responses. 
64
 Therefore, the model of CD4
+





allows the investigation of the role of IL-4Rα signalling on CD4
+
 T cells while maintaining 
IL-4/IL-13-mediated functions on non-CD4
+















In a recent study in our laboratory (unpublished), it has been demonstrated that IL-4Rα 
deletion on CD4
+
 T cells in an acute model of AAD promotes disease progression. There has 
been no studies documented that defines the direct role of IL-4Rα on CD4
+ 
T cells in chronic 
allergic airway disease and airway remodelling. In order to investigate the role of IL-4Rα on 
CD4
+ 
T cells in a long-term model of murine AAD, the present study utilised previously 






 These mice which have impaired IL-
4Rα signalling on CD4
+ 
T cells were sensitized and challenged with ovalbumin.  
 




 mice are significantly protected 
from AAD in comparison to littermate control mice sensitised and challenged with OVA (IL-
4Rα
-/lox




 mice demonstrated decreased disease pathology 
(although not significant) in airway inflammation, mucus hypersecretion, collagen deposition 
and airway remodelling compared to OVA littermate control mice (IL-4Rα
-/lox
). In addition, 




 mice when compared to OVA 
littermate control mice (IL-4Rα
-/lox





was confirmed by histology for fibrin and reticular fibres. Markers of AAMs such as 




 mice during OVA-induced 
AAD compared to OVA littermate controls (IL-4Rα
-/lox
). This observation could probably be 
a consequence of reduced Th2 cytokines and other factors produced by T cells. Together 
these data show that IL-4Rα dependent CD4
+
 T cells play an essential role in the 
pathogenesis of chronic murine AAD. However, it has been demonstrated that CD4 
independent mechanisms can also support recruitment and maintenance of inflammatory 
cells. Chemokines and cytokines secreted by airway epithelium, mast cells and eosinophils 
can also contribute to the inflammatory process. 
65-68 
Although it has been reported that CD4
+ 
T cells are required at later stages in establishing AAD, our data clearly demonstrate that IL-
4Rα dependent CD4
+ 
T cells contribute significantly to the pathology of chronic AAD. 
 
Our findings suggest two possibilities. Firstly, IL-4 dependent Th2 is important in chronic 
AAD and secondly, IL-4 inhibits CD4
+
 T cell mechanisms that downregulate chronic AAD. 




 mice still have IL-13 producing CD4
+
 T 
cells, albeit at decreased levels compared to littermate controls (IL-4Rα
-/lox
). Unpublished 
data from our group found that IL-13 signalling can occur via IL-13Rα2 which is known to 















The role of IL-17 in the pathogenesis of asthma has been studied. It has been established that 
IL-17, through the release of proinflammatory mediators contribute to the inflammation in 
asthmatics.
69
 Increased levels of IL-17 were observed in blood and airways of asthmatic 
patients. 
70, 71
 Human studies have shown the proliferation and increased airway smooth 
muscle (ASM) mass by Th17 cytokines indicating their role in airway remodelling. 
72, 73
 IL-
17F may have a crucial role in allergic airway inflammation, and have important therapeutic 




 mice had increased 
IL-17 and IFN-γ production by CD4
+
 T cells (from lungs) throughout the course of the 
model. While IL-17 has been shown to induce neutrophil-dependent airway hyperreactivity, 
it was also found to down-regulate established allergic airway inflammation and reduce 
airway hyperreactivity. 
74-77
 From a previous publication, it was shown that IL-17 produced 
by CD4
+
 T cells was important in downregulating airway inflammation in mice in a model of 
bleomycin-induced lung injury 
78
. However, human studies have found an association 
between IL-17 and severe asthma, which is often neutrophilic and corticosteroid resistant. 
79, 
80
 In addition, Th17 driven allergic airway inflammation was found to be steroid resistant in 
vivo. 
81 
The results presented here demonstrates the importance of IL-4Rα signalling on CD4
+ 
T cells 
and confirms that it is detrimental in chronic murine model of AAD. Further studies are 
required to understand the mechanism by which IL-4Rα on CD4
+
 T cells contribute to the 
pathology of AAD. Thus IL-4Rα signalling on CD4
+
 T cells plays an essential role in murine 
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IL-4Rα expression on Macrophages/Neutrophils is 
not required for chronic Allergic Airway Disease 
















3 IL-4Rα expression on Macrophages/Neutrophils is not required 





Alternative activation of macrophages is induced by the Th2 cytokines IL-4 and IL-13 
through IL-4Rα. Markers of alternatively activated macrophages (AAMs) are upregulated  in  
asthmatic lungs and mice with allergic airway disease (AAD), the role of IL-4Rα activated 





 mice deficient for IL-4Rα in macrophages and neutrophils, the in vivo effects of impaired 




The aim of this study is to investigate the chronic effects of AAD and the role of IL-4Rα 







AAD was introduced in mice by repeated subcutaneous sensitisation with 20 µg ovalbumin 
(OVA) adsorbed to 0.65% alum on days 0, 7, 14, and 21. On days 27 and 29 and then twice 
weekly for 4 weeks, mice were allergen challenged intranasally with 20 µg OVA in 50 µL 
PBS under anaesthesia. Mice were investigated for the presence of airway 
hyperresponsiveness (AHR), markers of allergic inflammation, allergen specific Th2 type 
antibody and cytokine production, arginase activity and nitric Oxide production. 
 
Results 
Airway hyperreactivity, Th2 responses, mucus hypersecretion, eosinophil infiltration, and 




 mice but AAM expression (Ym-1 























These findings demonstrate that there is no reduction in AAD in mice in the absence of IL-





Alternatively activated macrophages are associated with murine AAD and human asthma 
1, 2
. 
IL-4 and IL-13 induce alternative activation of macrophages through IL-4Rα. The role of IL-







Monocytes derived from pluripotent hematopoietic stem cells in the bone marrow continually 
migrate into the tissues where they mature into macrophages. Macrophages, the most 
abundant immune cells in the lung reside in the alveolar spaces of the lung contributing to the 
innate immune defense in the airways by expressing a variety of pattern recognition receptors 
like mannose receptors or β-glucan receptors
 3.4
. The two main subsets of lung macrophages 
are alveolar macrophages (AM) and interstitial macrophages (IM) which are phenotypically 
and functionally distinct. IMs express high levels of MHC II, show greater efficieny in 
stimulating T cell proliferation in vitro even though have lower phagocytic potential . Thus 
AMs and IMs have complementa y immunosuppressive effects with differential DC function 
and pulmonary immune responses.
5 
Upon an inflammatory stimulus, monocyte derived 
macrophages are recruited to the lung and in vivo studies have
 
demonstrated that both 
resident and recruited macrophages can alternatively activate and be driven to proliferate by a 
Th2 environment.
6 
Macrophages proliferate locally upon stimulation and are efficient in 
phagocytosing debris and microbes by production of inflammatory cytokines.
3,6,7 
and also in 




The activation of macrophages is important for their functioning 
7, 9 
and exhibit multiple 
phenotypes depending on the cytokine environment and disease context. The two 
conventional macrophage types identified were: classically activated macrophages (CAM) 
and alternatively activated macrophages (AAM).
10















phenotypes called oxidized phospholipid-treated murine macrophages (Mox) 
11
 and Tumour-




Th1-associated classically activated macrophages (CAM) are pro-inflammatory, activated by 
Th-1 cytokine IFN-γ, secrete TNF-α and involved in the upregulation of inducible nitric 
oxide synthase (iNOS), resulting in nitric oxide (NO) production by hydrolysis of L-arginine. 
caMphs mediate defence of the host by efficient bacterial killing and promotes extracellular 
matrix (ECM) degradation and apoptosis causing tissue damage.
13
 In contrast to the 
classically activated macrophages, the Th2-associated alternatively activated macrophage 
(AAMs) secretes ECM components such as trans-glutaminase, fibronectin and osteopontin. 
These macrophages got pro-fibrotic effects by eliciting immunity against multicellular 
pathogens, are anti-inflammatory and regulate wound healing. 
6, 14
 Mox macrophages show 
decreased phagocytotic and chemotactic capacity whereas TAMs suppress antitumour 
immunity. 
 
IL-4/IL-13–activated alternative macrophages (AAMs) are characterised by IL-4Rα-driven 
increased arginase-1 expression,
7,9,15,16
 induction of chitinase and FIZZ family members 
(ChaFFs)
17
 and chitinase-like molecules (e.g.Ym-1), 
17-19
 along with other biomarkers such as  
peroxisome proliferator-activated receptor γ (PPAR γ) and mannose receptor (MR). The 
enzyme Arginase-1, a marker gene for alternative activation 
7
 uses L-arginine as a substrate 
to produce L-ornithine and urea 
20
. These products are then used in the biosynthesis of proline 
and polyamines 
9, 20.
 AAMs produce increased levels of arginase-1 thereby supressing NO 
production. Prolines are precursors of collagen and are associated with the construction of 
ECM. Polyamines are molecules associated with cell proliferation and are important in the 
generation of connective tissue, smooth muscle, and mucus.
7,9.15
 Thus the production of 
arginases constitute an array of anti-inflammatory, tissue repair and pro-fibrotic-associated 
responses.
21
 L-arginine is the same substrate used by the CAM-associated iNOS and thus 




IL-4Rα-responsive macrophages which are capable of developing into the alternatively 




. Alternatively activated macrophages, or M2 macrophages, have been associated with 
the control of inflammation 
22,23
















, and tissue damage 
25
in the lung. Additionally, AAMs have been shown to control viral-




It has been hypothesized that the pathogenesis of AAD is contributed by AAMs by increased 
levels of arginase production and by synthesising proline and polyamines, the molecules 
involved mainly in the generation of connective tissue, smooth muscle, and mucus. Studies in 
both mouse models and human studies have demonstrated an upregulation in markers of 
AAMs such as arginase, found in inflammatory zone 1 (FIZZ-1), chitinases, and chitinase-
like proteins in the allergic lung.
 2, 27, 28
 AAMs were thought to play an important role in 
asthma by inhibiting the production of NO which is necessary for the regulation of airway 
and vascular tone. It also promotes the synthesis of collagen and other connective tissues 
2,22,29,30
 increased secretion of mucus 
29
 and recruitment of eosinophils.
22, 31 
 
However, other studies have demonstrated that AAMs may have regulatory or suppressive 
properties. Infection with nematodes such as Heligmosomoides polygyrus and 
Nippostrongylus brasiliensis in mice showed that induction of AAM by memory Th2 cells 
mediated a protective immune response against the parasite 
32
 leading to the induction of 
AAM in the lung.
25,33 
Infection with other nematodes such as that of Brugia malayi, have 
shown that AAMs suppress CD4
+





alternative activation of macrophages can occur without adaptive immunity, contributing to 
wound healing 
22
. AAMs are also involved in downregulating a harmful Th1 immune 
response 24 when mice were infected with Schistosoma mansoni. Chronic pulmonary 
infection of Cryptococcus neoformans in mice was accompanied with induction of AAM 
leading to the development of symptoms similar to allergic asthma.
35,36 
AAMs were also 




 experimental autoimmune 
encephalomyelitis,
39
 lung fibrosis 
40,41




Mouse models of AAD have shown induction of AAM in the lung after allergen challenge. 




 was dependent on IL-4Rα signalling in an ovalbumin model of allergic 
asthma.
30,45,46 
Arginase 1 inhibition by RNA interference attenuated IL-13 induced allergic 
symptoms.
47 
 In addition, IL-13Rα1 signalling is not necessary to induce AAM differentiation 

















asthma patients, the numbers of AAM were increased in comparison to healthy controls 
1
 and 







number of airway macrophages was found both in patients 
with asthma 
49-51,54
 and animal models of AAD 
52-53
 . On the contrary, other studies in rats and 
mice showed suppression of allergic symptoms by the modulation and phagocytosis function 
of alveolar macrophages and allergen-loaded macrophages. 
55-58
 However this suggests that 
macrophages may play an important role in allergic inflammation of the lung but the exact 
role of AAM in AAD still needs to be established. 
 
Therefore, we aimed to test the hypothesis that IL-4Rα dependent AAMs contribute to 




 mice, which have abrogated IL-4Rα 
signalling on macrophages and neutrophils. Our results demonstrate no reduction in allergic 
airway disease in the absence of IL-4Rα dependent AAMs, suggesting that AAMs may not be 


































3.3 Materials and Methods 
 
Mice 












 on a 
BALB/c background were housed in independently ventilated cages under specific pathogen-
free conditions in the University of Cape Town Animal Facility. Animal procedures were 
approved by the University of Cape Town Animal Ethics Committee. (Permit Number: 
008/016) 







 were generated by mating floxed IL-4Rα
lox/lox





 These mice were then back-crossed to the BALB/c background 













 BALB/c mice. IL-4Rα
-/lox
 littermates and IL-
4Rα
-/-
 mice were used as controls in all experiments. 
 
Genotyping of IL-4Rα knockout mice 
Mice were genotyped via PCR to determine what IL-4Rα allele was present and the PCR 
conditions were as follows: 94°C/30 s; 57°C/30 s, 72°C/1 min for 40 cycles on an MJ 
thermocycler (Biozym, Hessisch, Oldendorf, Germany). 
Primers for PCR screening of the mice 
Lys M Cre Transgene allele 
M lys1:    5’- CTT GGG CTG CCA GAA TTT CTC -3’ 
Cre Antisense:   5’- CCC AGA AAT GCC AGA TTA CG -3’ 
 
IL-4R Wildtype allele 
Exon 7 forward1:      5’-TGA CCT ACA AGG AAC CCA GGC-3’  
Exon 8 reverse:  5’-CTC GGC GCA CTG ACC CAT CT-3’  
 
IL-4R Deleted allele 
IL-4Rα KO P1:  5’ - GGC TGC TGA CCT GGA ATA ACC - 3’   
IL-4Rα KO P2:    5’ - CCT TTG AGA ACT GCG GGC T - 3’ 
Conditional IL-4R LoxP allele 
IL-4Rα KO P1:  5’ - GGC TGC TGA CCT GGA ATA ACC - 3’  
















Sensitisation and challenge of mice  
Mice were sensitized subcutaneously with 20 µg ovalbumin (OVA) adsorbed to 0.65% alum 
on days 0, 7, 14, and 21. On days 27 and 29 and then twice weekly for 4 weeks, mice were 
administered intranasal challenges with 20 µg OVA in 50 µL PBS under anaesthesia. 
61 
 
Measurement of Airway Hyperreactivity 
Airway resistance and elastance of the whole respiratory system (airways, lung chest wall) 
after challenge with increasing doses of acetyl-b-methylcholine (methacholine, Sigma-
Aldrich, Aston Manor, South Africa) were determined by forced oscillation measurements as  
described 
62
 with a Flexivent system (SCIREQ, Montreal, Canada) by using the 
singlecompartment (‘‘snapshot’’) perturbation. Differences in the dose-response curves were 
analyzed by repeated-measures ANOVA. Only mice with acceptable measurements for all 
doses (coefficient of determination >0.95) were included in the analysis.  
 
Flow cytometry 
Bronchoalveolar lavage (BAL) cells were obtained by flushing the lungs of sacrificed mice 
once with 1 mL PBS/1% FCS. 
 
Single-cell suspensions were prepared from lungs after digestion for 1 hour at 37°C in 
Iscove’s Modified Dulbecco’s Medium (IMDM) (Invitrogen,Carlsbad, Calif) containing 13 
µg/mL DNase I (Roche, Randburg, South Africa) and 50 U/mL collagenase IV (Sigma-
Aldrich, Aston Manor, South Africa) ).  
 
For intracellular cytokine staining, lung cells were incubated at 37°C for 4 hours with phorbal 
myristate acetate (Sigma-Aldrich) (50 ng/mL), ionomycin (Sigma-Aldrich) (250 ng/mL), and 
monensin (Sigma-Aldrich) (200 mM in IMDM/10% FCS). Cells were stained with CD3-
fluorescein isothiocyanate (clone 145-2C11) and CD4-PerCP (clone L3T4) (BD Bioscience), 
and intracellular cytokines were stained with anti–IL-4 (clone 11B11), anti–IL-5 (clone 
TRFK5), anti-IFN-γ (clone XMG 1.2), anti-IL-17 (clone TC11-18H10) (BD Bioscience), 
anti–IL-13 (clone eBio 13A) (eBioscience, San Diego, Calif), and rat anti-mouse IgG1 
isotype control (clone A85-1) (BD Bioscience) (all PE-labeled). Cells were acquired on a 
FACSCalibur machine (BD Immunocytometry Systems, San Jose, Calif), and data were 
















For flow cytometry, the following antibodies were used: SiglecF-PE (clone E50-2440), 
CD11c-APC (clone HL3), CD4-PerCP (clone L3T4), with streptavidin (all BD Bioscience, 
Erembodegem, Belgium), CD3 FITC fluorescein isothiocyanate (clone 145-2C11) and GR-1-
fluorescein isothiocyanate (clone RB68C5). 
 
Sorting of alveolar macrophages 




 cells from the pooled lungs of OVA-
sensitized and -challenged mice. Cells were sorted on a FACSVantage flow cytometer (BD 
Immunocytometry Systems, San Jose, Calif). Purity was determined by flow cytometry and 
checked by cytospin and staining with the Rapidiff Stain set (Clinical Diagnostics CC, 
Southdale, South Africa) and was at least 99%. 
 
Arginase assay 







 mice were plated in triplicates in 96-well plates at 2x10
4
 cells per well 
in IMDM (containing 10% FCS, 100 U/ml penicillin G, 100 μg/ml streptomycin) in the 
presence or absence of 100 ng/mL LPS (Sigma-Aldrich). Culture plates were then incubated 
at 37 ºC for 72 hours and following stimulation, cells were washed repeatedly with 1X PBS 
and lysed with 0.1% TritonX-100. Lysates were incubated with 50 μl of 10 mM MnCl2 and 
50 mM Tris HCl (pH 7.5) to activate the enzyme for 10 minutes at 55°C. 25 μl of the lysate 
solution was then transferred to 1.5 ml eppendorf tubes with 25 μl 500mM L-Arginine (pH 
9.7) and incubated for 1 hour at 37ºC. The reaction was then stopped using 400 μl of acid 
mixture (H2SO4:H3PO4:H2O at a ratio of 1:3:7). Thereafter, the colorimetric reaction was 
initialised by adding 25ul of 9% α-Isonitrosopropiophenone (ISPF) and incubated at 100ºC 
for 45 minutes, followed by 10 minutes in the dark (at room temperature). 200 μl aliquots 
were added and serially diluted, three-fold, in ddH2O on a 96-well plate (Nunc Maxisorb) and 
read at 540 nm on a VersaMax microplate reader. Controls had ddH2O instead of L-Arginine 
and blanks had ddH2O added instead of cell lysates. Standards consisting of doubling 
dilutions of 1000 g/ml urea were treated under identical assay conditions. Arginase activity 


















Nitric oxide (NO) measurements 







 mice were plated in triplicates in 96-well plates at 2 x 10
5
 cells per 
well in IMDM (containing 10% FCS, 100 U/ml penicillin G, 100 μg/ml streptomycin) in the 
presence or absence of 100 ng/mL LPS (Sigma-Aldrich). Cell culture supernatants were 
analysed for the production of NO using the Griess reaction assay, which measures the 
concentration of nitrite, a stable liquid product from the reaction of NO with O2. Supernatant 
samples of re-stimulated lung cells were collected after 72 hours of incubation at 37ºC and 
stored at –20ºC until analysis. Supernatant samples were serially diluted three-fold and 
standards (1mM NaNO2 solution) were serially diluted two-fold in IMDM (supplemented 
with 10% FCS, 100 U/ml penicillin G, 100 μg/ml streptomycin) in a total volume of 50 μl per 
well in a flat bottomed 96-well plate (Nunc Maxisorb). 25 μl of Griess Reagent 1 (1% 
sulfanilamide in 2.5% phosphoric acid) and then 25 μl of Griess Reagent 2 (0.1% napthyl-
ethylene-diamine in 2.5 % phosphoric acid) were sequentially added to each well. The plate 
was incubated at room temperature for 5 minutes to allow the reaction to develop. The 
colorimetric reactions were read at 540 nm and the reference wavelength at 690 nm using a 
VersaMax microplate reader. The absorbance reading of the samples (in OD units) was 
correlated to the nitrite concentration (in mM) as calculated by the standard curve.  
 
RNA extraction, cDNA synthesis and Quantitative RT-PCR 
Total RNA was extracted from sorted alveolar macrophages of >98% purity by using Tri 
reagent (Applied Biosystems, Carlsbad, Calif) according to the manufacturer’s protocol and 
purified with RNeasy Microprep kit (Qiagen Hilden, Germany). Sorted alveolar macrophages 
were lysed in 500 µl TriReagent® (Molecular Research, USA) and stored at -80 °C. To 
extract the RNA, thawed samples were incubated at room temperature for 5 min to ensure 
complete dissociation of nucleoproteins. To each sample, 0.1 ml of chloroform was added 
and samples were vortexed for 15 seconds and incubated at room temperature for a further 15 
min prior to centrifugation at 12000 rpm for 15 min at 4 °C. The RNA contained in the upper 
aqueous layer was purified using the miRNeasy Mini Kit (Cat. No. 217004, Qiagen, USA), 
RNeasy MinElute Cleanup Kit (Cat. No. 74204, Qiagen, USA) and the RNase-Free DNase 
Set (Cat. No. 79254, Qiagen, USA). RNA quantity was determined using a Nanodrop 
ND1000 (Thermo Scientific, USA) and the integrity was determined using the Agilent RNA 















Kit (Cat. No. 5067-1548, Agilent Technologies, USA) on an Agilent 2100 Bioanalyzer 
(Agilent Technologies, USA). The Agilent assays were performed by the Centre for 
Proteomic and Genomic Research, Cape Town.  
 
cDNA was synthesized with Transcriptor First Strand cDNA synthesis kit (Roche). Real-time 
quantitative PCR was performed on cDNA samples to determine gene expression levels of 
marker genes by using Lightcycler FastStart DNA MasterPLUS SYBR Green I reaction mix 
(Roche) on a lightcycler 480 II (Roche). Each reaction contained SYBR® Green Master Mix 
(Cat. No. 04913850001, Roche, Germany), primers and cDNA template. Reactions were 
prepared in 96- or 384-well plates (Roche, Germany) using a QIAgility robot (Qiagen, USA) 
and PCRs were performed in a LightCycler® 480 (Roche, Germany). Primers for inducible 
nitric oxide synthase (iNOS), arginase, Ym-1, and FIZZ-1 have been previously described 
and are listed in table 3.1 
66
   Gene expression levels were normalized according to the 




Table 3.1: RT-PCR primers and PCR conditions 
 



































































Histology and immunohistochemistry 
Lungs were fixed in 4% formaldehyde/PBS and embedded in paraffin. Tissue sections were 
stained with haemotoxylin and eosin (H&E), periodic acid-Schiff (PAS) for mucus, Sirius red 
for collagen, Martius scarlet blue (MSB) for fibrin and Gordon and Sweets for reticulin 
(reticulin silver staining kit). Image analysis was performed on NIS Elements (Nikon 
Instruments, Tokyo, Japan). Lung sections from individual mice were assessed, and data from 
3 experiments were pooled. 
 
Antibody ELISAs 
Blood samples taken by tail vein bleeding or directly from mice after sacrificing were 
collected in plasma separator tubes (MicrotainerTM SST, BD, USA). Samples were 
centrifuged for 20min at 6000rcf and stored at -80ºC. OVA specific antibodies were 
measured in blood serum by endpoint titration ELISA. For OVA specific antibodies, 96 well 
ELISA plates (Maxisorp, Nunc, Denmark) were coated overnight with 50µl OVA in PBS 
(5µg/ml for IgG1, IgG2a, IgG2b or 1mg/ml for IgE). For total IgE ELISA, plates were coated 
with anti-mouse IgE antibody (clone 84.1C, 1/1000 dilution). Plates were blocked for 1h at 
37ºC with 200µl 2% fat free milk powder in PBS. Serial dilutions of serum samples in 50µl 
PBS/ 0.1% BSA were added to the wells and plates were incubated overnight at 4 ºC. 
Purified recombinant mouse IgE (BD, USA) was used as a standard for total IgE ELISA, at a 
starting concentration of 1µg/ml. 50µl alkaline phosphatase conjugated goat anti-mouse 
isotype specific antibodies (Southern Biotechnology, USA) at a 1/1000 dilution in PBS/ 0.1% 
BSA were added to the wells and the plates were incubated for 3h at 37ºC. Subsequently, 
plates were incubated with 50µl pnitrophenylphosphate (Fluka, Switzerland) and colour 
reaction was stopped with 50µl 1M NaOH. Absorption was measured at 405nm with 492nm 
as reference wave length using a VersaMax plate reader (Molecular devices, USA). Plates 
were washed 4x with 200µl per well after each incubation. 
 
Statistical analysis 
P values were calculated in GraphPad Prism 4 (GraphPad Software, Inc, San Diego, Calif) by 
using ANOVA with Bonferroni’s posttest or repeated measures ANOVA, and results are 
























 mice are not protected against the development of AHR 
 




 mice and littermate controls were examined in 
OVA-induced allergic airway disease. Airway resistance (R) and elastance (E) were 
measured in response to increasing doses of methacholine after chronic exposure to OVA. 
Airway dynamic resistance (R) quantitatively assesses the level of constriction in the lungs. 
Increased R values signal constriction of the lungs and this parameter reflects not only central 
airway resistance, but is also influenced by the lung periphery (the "tissues").Dynamic 
elastance  (E) captures the elastic rigidity of the lungs and reflects the mechanical properties 
of the lungs for normal respiratory rates. Increased E values signal an increased stiffness of 
the lungs.  
 
The OVA sensitised and challenged mice developed AHR, with significant differences 
between IL-4Rα
-/lox







mice (Fig.1 A, B). A trend toward a slight, but not significant, increase in both airway 




 mice compared to IL-4Rα
-/lox
. 
littermate controls. Global IL-4Rα
-/-
 mice did not show a significant increase in AHR 
compared with saline controls, demonstrating protection. Since airway resistance assesses 





 mice and littermate controls. These results provide strong evidence that 
























 OVA mice are not protected against AHR. Airway 





mice compared to IL-4Rα
-/lox
 PBS mice. N= 10-16 mice, pooled data from three individual 
experiments.  Significant differences between IL-4R
-/lox





are represented by stars (*p<0.01, ***, P<0.001). P values are in comparison to individual 















3.4.2. Markers of allergic inflammation (Airway infiltration, mucus production and 






During AAD, as a consequence of OVA sensitisation and challenge inflammatory cells were 
recruited to the lungs around airways and blood vessels. Airway infiltration of the lung tissue 
with inflammatory cells, goblet cell hyperplasia and collagen deposition was not affected by 
loss of IL-4α on macrophages and neutrophils (Figs 2, 3). Analysis of the cellular 






 mice sensitised and 
challenged with OVA both had significantly increased percentages of eosinophils compared 
with PBS controls (Fig 2A). IL-4Rα
-/- 
OVA mice showed significant increase in percentage 







sensitised and challenged with OVA showed decreased percentages of neutrophils similar to 






 OVA mice had increased 
mucus hypersecretion (quantified by image Analysis on NIS Elements software) compared 
with PBS controls but abrogated in the global IL-4Rα
-/-










































 mice sensitised and challenged with OVA compared to IL-4Rα
-/lox
 mice sensitised and 







 mice sensitised and challenged with OVA mice but 
abrogated in the global IL-4Rα
-/-
 mice.  N= 8-12 mice, pooled data from two different 
experiments. Significance was to IL-4Rα
-/lox























 mice (Fig. 3B, D). Mucus hypersecretion by goblet cells is a characteristic 
of AAD. Histological examination of lungs stained with PAS showed no signs of mucus 
hypersecretion in the airways of PBS sensitised and challenged IL-4Rα
-/lox
 mice (Fig. 3E) and 
IL-4Rα
-/-
 OVA mice (Fig. 3G).  OVA sensitised and challenged littermate control IL-4Rα
-/lox
 




 mice (Fig. 3H) revealed mucus hyper secretion 
showing similar severity of goblet cell hyperplasia. Sirius red staining showed increased 
collagen deposition around airways and blood vessels in IL-4Rα
-/lox





 mice (Fig. 3L) compared to the mice sensitised and challenged with saline 
/PBS (Fig. 3I) and OVA sensitised and challenged  IL-4Rα-/- mice (Fig. 3K) . 
 













OVA mice. Literature 
suggested that AAMs may play an important role in collagen deposition through increased 
production of prolines. However our data illustrate that IL-4Rα dependent AAMs are not 
necessary for the development of OVA-induced allergic airway inflammation and do not 
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Figure 3. Airway infiltration of the lung tissue with inflammatory cells, goblet cell 
hyperplasia and collagen deposition is not affected by loss of IL-4α on macrophages and 
neutrophils. Lung sections from IL-4Rα
-/lox
 mice sensitised and challenged with saline /PBS 
(A) and OVA sensitised and challenged  littermate control IL-4Rα
-/lox
 mice (B), IL-4Rα
-/-
 




 mice (D) were stained with H&E. Mucus hypersecretion by 
goblet cells were stained with PAS in the airways of  PBS sensitised and challenged IL-4Rα
-
/lox
 mice (E) and OVA sensitised and challenged  littermate control IL-4Rα
-/lox
 mice (F), IL-
4Rα
-/-




 mice (H). Collagen deposition around airways and 
blood vessels were illustrated by Sirius red staining in IL-4Rα
-/lox
 mice sensitised and 
challenged with saline /PBS (I) and OVA sensitised and challenged  littermate control IL-
4Rα
-/lox
 mice (J), IL-4Rα
-/-




















Fibrin deposition occurs as a result of inflammatory reactions in AAD. Martius Scarlet blue 
staining showed increased fibrin mass around the airways of OVA sensitised and challenged 
IL-4Rα
-/lox
 littermate control mice (Fig. 4B) compared to IL-4Rα
-/lox
 PBS mice (Fig. 4A) . IL-
4Rα
-/-




 OVA mice 
revealed increased fibrin mass around the airways (Fig. 4D) similar to IL-4Rα
-/lox
 OVA mice. 
 
In chronic AAD, airway remodelling includes structural changes such as epithelial shedding 
and increased subepithelial collagen deposition. Reticulin silver staining showed increased 
thickness of basement membrane and loose arrays of reticulin fibres in the airways of OVA 
sensitised and challenged IL-4Rα
-/lox





OVA mice (Fig. 4H). Control IL-4Rα
-/lox
 PBS littermate control mice and IL-4Rα
-/-
 OVA 
mice showed thick array of reticulin fibres showing the absence of airway remodelling (Fig. 


























mice. Lung sections from IL-4Rα
-/lox
 mice sensitised and challenged with saline /PBS (A) and 
OVA sensitised and challenged littermate control IL-4Rα
-/lox
 mice (B), IL-4Rα
-/-





 mice (D) were stained with Martius scarlet blue. Increased fibrin threads 
(stained red) were observed in the airways of OVA sensitised and challenged IL-4Rα
-/lox
 mice 




 mice (D). Epithelial thickness and subepithelial collagen 
deposition were illustrated by reticulin fibre staining. OVA sensitised and challenged 
littermate control IL-4Rα
-/lox




 mice (H) showed loose arrays 
of reticular fibres (stained black) around the alveolar walls and increased collagen deposition 



































 is similar to IL-4Rα
-/lox
 
littermate control mice and is predominantly a Th2-type response. OVA specific 
antibodies were measured by end point titration ELISA. IgG1 (A), IgG2a (B), IgG2b (C) 





















In order to investigate if the antibody responses to chronic OVA sensitisation and challenge 



























/lox mice compared to IL-4Rα-/- mice indicated a predominant Th2-type response. (Fig 5 A, 
B,C). 
 







 mice sensitised and challenged with OVA compared to 
those of IL-4Rα
-/lox
 PBS and IL-4Rα
-/-








 and  
IL-4Rα
-/lox
 littermate control mice showed similar increase. OVA specific IgE (A) and 
total IgE (B) antibodies were measured by end point titration ELISA. Significant differences 
to IL-4Rα
-/lox 
PBS mice (*, p<0.05, ** p<0.01), Significant differences to IL-4Rα
-/lox 
OVA 


















The percentages of IL-4, IL-5 and IL-13 producing CD4
+
 T cells was significantly increased 










mice compared with PBS 
littermate controls. The percentage of IFNγ producing CD4
+
 T cells was significantly 
decreased in the lungs of IL-4Rα
-/lox 
OVA mice compared with PBS littermate controls. Only 






mice compared to OVA littermate control 
mice. IL-17 production was significantly increased only in IL-4Rα
-/- 
OVA mice. (Fig 7) 
Therefore, the absence of IL-4Rα dependent AAMs did not reduce Th2 responses or affect 






















 mice. Lung cells were incubated at 37°C for 4 hours with phorbal 
myristate acetate (PMA), ionomycin and monensin for intracellular cytokine staining. 
Significant differences to IL-4Rα
-/lox
 mice sensitised and challenged with PBS. N=5-8 mice, 
pooled data from two individual experiments. Significant differences to IL-4Rα
-/lox
 mice 




















described earlier. There was a significant reduction of arginase activity and significant 






Figure 8.  Reduced arginase activity and increased Nitric Oxide (NO) production. 




 mice showed significant decrease in arginase 






























Alveolar macrophages from OVA sensitised and challenged mice were sorted. mRNA 
expression of markers for classical activation (iNOS) and alternative activation (Ym-1,  
FIZZ-1, and Arg-1) was quantified using RT-PCR using rs12 housekeeping gene for 
normalising.IL-4Rα
-/lox
 mice showed alternative activation of macrophages as there was 
increased expression of Ym-1, FIZZ-1, and arginase in comparison to saline controls. (Fig. 8 





 mice compared to IL-4Rα
-/lox
 mice and. iNOS expression was increased 




Figure 9.  mRNA expression in alveolar macrophages normalized with rs12 
housekeeping gene. Expression of Ym-1(A), Fizz-1 (B) and arginase were reduced and 




 mice compared to IL-4Rα
-/lox 
PBS 

















The pathology of allergic asthma involving the contribution of cytokines such as IL-4  and 
IL-13 and it receptor IL-4Rα is well understood.
63-66
 The role of AAMs in Th2 driven 






has been reported. 
Ovalbumin induced mouse model have also revealed the role of AAMs in the aggravation of 
allergic airway inflammation. 
68 
  However, the role of AAMs in AAD remains unclear.  To 
date, there is no clear evidence that exists to indicate that AAMs directly play a role in AAD 
although an upregulation of AAM markers in murine AAD and human asthma has been 
shown.
1,9,74
 Previous studies from our group have demonstrated the expression of AAM 
markers that are IL-4Rα independent.
69,70 
  Other parasitic model studies such as Schistosoma 
mansoni conducted by our co-workers have proven the suppression of fibrosis by AAMs 
expressing certain molecules.
69
 Human and mice studies has demonstrated, enhanced 
eosinophilic inflammation in the presence of AAMs.
20, 71-83 
 





 either by suppressing T cell proliferation and activation 
after exposure to inhaled antigens. An exacerbation of AHR, eosinophil inflammation and 
Th2 cytokine secretion due to depletion of alveolar macrophages has also been reported.
 87   
It 
is known that interstitial macrophages suppress AAD through the production of IL-10 .
5 
AAMs downmodulate inflammation in several disease models 
24, 37, 39  
and their role in the 
suppression of T-cell proliferation has been demonstrated. 
6, 15, 26, 37, 42, 43, 88
. In helminth 
models, it has been demonstrated that FIZZ-1 (a marker of AAM) regulates Th2 responses 
and associated inflammation negatively.
89 
 
A previous study from our group has demonstrated that the presence of AAMs is not required 
for the onset of AAD in an acute model.
90
 In this study, we investigated the cell specific 





mice which have impaired IL-4Rα signalling in macrophages and neutrophils and 
therefore lack IL-4/IL-13–induced activation of macrophages through IL-4 receptor types 1 
and 2 were sensitised and challenged with ovalbumin. In comparison to IL-4Rα
-/lox
 mice 
sensitised and challenged with PBS. We observed a significant and consistent increase in 




mice similar to that of OVA littermate 
controls (IL-4Rα
-/lox



















 mice were similar to littermate 
controls inspite of impaired activation of AAMs. This observation suggests that IL-4Rα–
dependent AAMs do not play an important role in the regulation of collagen deposition, as 
suggested on the basis of their expression of arginases. Hence, demonstrating that IL-4Rα 
dependent AAMs are not necessary in the pathogenesis of murine AAD. It is known that 
arginases compete with nitric oxide synthases (NOS) for the substrate arginine. While NOS 
uses arginine to produce bacteriocidal NO, arginases convert arginine into ornithine and urea, 
with downstream products that include proline and polyamines, used in collagen synthesis 




Mimicking previous studies, 
2, 27, 28, 82, 91-94
 there is an upregulation of AAM markers such as 
arginase, Ym-1, and Fizz-1 in OVA littermate control mice (IL-4Rα
-/lox
) mice during OVA-
induced allergic airway disease. We observed an impaired expression of these markers on 




 mice, although they still exhibited a slight 
increase compared to the PBS littermate control mice (IL-4Rα
-/lox
). Based on the results 





suggests that AAMs are not involved in the recruitment of eosinophils. It has been 
established in murine studies that AAM marker does not contribute to AAD
96 
which 
corresponds to our findings. Hence it is also vital to understand the mechanism by which 
alternative activation influences the phenotype of distinct macrophage populations. However, 
other murine studies haves shown that adoptive transfer of IL-4Rα
+/+
 M-CSF-dependent 
macrophages in the presence of Th2 cells, significantly contributed to OVA-induced 
recruitment of eosinophils to the lung.
97
 In addition, stimulation of macrophages through IL-
4Rα result in their alternative activation enhancing the Th2-driven allergic inflammatory 




In conclusion, our results suggest that association between alternatively activated 
macrophages and allergic airway disease does not translate into a pathological role for these 
cells in AAD. This suggests that IL-4Rα activated AAMs are merely bystander cells 
responding to the Th2 cytokines. They do not play a significant role in the pathology of AAD 
and are not detrimental in murine AAD. Airway hyperreactivity was increased in the absence 
of AAMs, suggesting that the presence of alternative activation of macrophages in AADs 
may be an attempt to downregulate excessive immune effector responses. Despite the 















cell types are essential in the development of AHR and pathology of AAD. Thus AAMs in 
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The aim of this study is to investigate the cell specific contributions of IL-4Rα signalling on 
the outcome of Ovalbumin-induced chronic allergic airway disease (AAD) in mice. 
Specifically we aimed to investigate the role of IL-4/IL-13 responsive CD4
+ 





 mice and the role of IL-4/IL-13 induced alternatively activated 






Allergic asthma shows Th2 inflammatory responses in the lung orchestrated by CD4
+
 T cells. 
Most murine models and human studies have shown that CD4
+
 T cells infiltration around the 
airways and eosinophil recruitment are key events of the inflammatory process contributing 
to disease severity.
 
The direct role of IL-4Rα on CD4
+ 
T cells in chronic allergic airway 





 mice were sensitized and challenged with ovalbumin.  
 




 mice to be significantly protected from 
AAD in comparison to OVA IL-4Rα
-/lox
 littermate control mice showing a significant 
decrease in AHR, airway inflammation, mucus hypersecretion, collagen deposition and 
airway remodelling. Although it has been characterised that CD4
+ 
T cells are required at later 
stages in establishing AAD, our data provides a strong clue that IL-4Rα dependent CD4
+ 
T 
cells contribute significantly to the pathology of chronic AAD. The results presented here 
clearly demonstrate the importance of IL-4Rα signalling on CD4
+ 
T cells. Our first major 
conclusion from the study is that IL-4Rα signalling on CD4
+
 T cells plays an essential role in 
murine AAD.  
 
IL-4, IL-13 and its receptor IL-4Rα’s role in the pathology of allergic asthma has been 
understood well. The contribution of AAMs to certain Th2 driven pathologies has also been 
studied. The role of AAMs in the aggravation of allergic airway inflammation has been 
confirmed in Ovalbumin-induced mouse model.  However, the role of AAMs in AAD has 
remained unclear and no clear evidence exists yet to show that AAMs directly play a role in 
allergic airway disease although an upregulation of AAM markers was observed in murine 






















mice which lack IL-4Rα signalling in macrophages and 
neutrophils and therefore lack IL-4/IL-13–induced activation of macrophages through IL-4 
receptor types 1 and 2 were sensitised and challenged with ovalbumin. In comparison to IL-
4Rα
-/lox
 mice sensitised and challenged with PBS, we found a significant and consistent 




mice after methacholine 
challenge similar to littermate controls. AHR, airway inflammation, mucus hypersecretion, 




 mice were similar to 
littermate controls inspite of impaired activation of AAMs suggesting that IL-4/IL-13 
induced IL-4Rα–dependent alternatively activated macrophages (AAM) do not play an 
important role in the pathogenesis of chronic murine AAD.  
 
Our second main conclusion highlighted the association between alternatively activated 
macrophages and AAD which does not translate into a pathological role in AAD suggesting 
that IL-4Rα activated AAMs do not play a key role in the pathology of AAD .This provides a 
strong evidence that AAMs in allergic airway disease may be merely associative but not 
causative and is a result of elevated Th2 responses. 
 
 
 
 
 
 
